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CHAPTER 1  
Introduction to metabolomics 
Metabolomics is the characterization of low molecular weight compounds 
(molecular weight < 1500 Da) in biofluids1, 2, 3, tissues4, 5, 6, 7  and cells8, 9, 10 to get insights 
of the perturbation to an organism caused by diseases, aging11 or external stimuli12, 13, 14, 
15, 16 (e.g. drug treatment).   It is the most relevant to phenotypes as compared with other 
“Omics” studies17 (Figure. 1.1). Research fields of metabolomics include sample 
preparation and extraction for metabolic profiling, disease biomarker discovery, drug 
toxicity study, bioinformatics study (e.g. application of classification and prediction models) 
and data processing approaches related to specific analytical techniques such as Nuclear 






Figure 1.1 The correlation of different "omics" studies. Metabolomics shows the closest relevance to 
the phenotype.17   
1.1 Metabolic profiling by NMR 
NMR is widely used in metabolic profiling to identify and quantify metabolites.  This 
is because it allows non-destructive measurement of a variety of structurally different 
metabolites.  Moreover, quantification is easily achieved based on the peak area of the 
specific metabolite related to the peak area of a known concentration of the internal 
standard.  External reference compounds can also be used for the quantification of 
metabolites by inserting a co-axial capillary containing the solution of the reference 
compound into the NMR tube during measurement18.  Moreover, NMR exhibits high 
reproducibility of measurement, and requires minimum sample preparation as compared 
with other techniques such as mass spectrometry (MS).   
The drawback of NMR lies in the low sensitivity of detection. The sensitivity is 
related to the gyromagnetic ratio (γ) of the nuclear spins, experiment acquisition time and 





observed etc.  Metabolite concentrations ranging from µM to mM can be readily detected 
by 1D NMR in ~10 min. Increased signal/noise and spectral resolution can be achieved 
by the application of a higher magnetic field instrument and cryoprobe to reduce thermal 
noise19.  Commonly, isotopic enrichment of the metabolites through chemical reactions 
can be applied to enhance the sensitivity of heteronuclear 2D NMR experiment20, 21, 22.  
1.1.1 NMR experiments for different sample types 
Biofluids such as serum, plasma, urine, amniotic fluid, cerebrospinal fluid, saliva 
and other digestive fluids can be analyzed by liquid state NMR spectroscopy, usually with 
a 1D 1H NMR experiment for high throughput metabolic profiling.  Solvent suppression is 
required during the measurement due to the large water signal dominating the spectrum.  
Water presaturation by applying a weak radiofrequency (RF) during the relaxation/mixing 
time and WATERGATE (WATER suppression by GrAdient-Tailored Excitation) are the 
two most frequently used approaches for water suppression23, 24.  Another method, 
excitation sculpting by water-selective suppression using pulsed field gradients is also 
reported to be convenient when detecting small molecules25.  For samples containing 
minimum proteins and lipids (e.g. urine), phosphate buffer made in D2O can be added to 
the sample and measured by a single pulse NMR experiment with water suppression.  
Whereas for biofluids containing macromolecules (e.g. blood serum), T2 relaxation editing 
by Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence in NMR experiment is utilized to 
attenuate broad resonances from proteins and lipids which have short T2 relaxation time26.  
Alternatively, sample preparation such as deproteinization by reaction with organic 
solvents or ultrafiltration can be used and the resulting metabolite extract measured by a 





 Metabolic profiling of intact tissues and cells is important in obtaining biochemical 
information with minimum perturbation to the sample as well as retaining the sample for 
subsequent histopathological analysis.  The nondestructive detection can be achieved 
using solid state magic-angle spinning (MAS) NMR with CPMG and water suppression 
pulse sequence to minimize the spectral line broadening5, 27.   Standard processes for 
sample preparation are freezing the tissues in liquid nitrogen to quench the enzymatic 
reactions, followed by grinding the tissue in a cooled mortar or with an electric 
homogenizer.  Then the tissue sample is packed into the rotor with the addition of D2O 
for signal locking during NMR measurement.  Inserting the sample rotor into the NMR 
probe at an angle of 54.7° relative to the external magnetic field B0 and spinning the rotor 
will result in narrow linewidth due to the cancelation of the orientation dependent chemical 
shift anisotropy (CSA) and dipolar coupling effects in the solid samples.   Moreover, 
experiments should be conducted at a low temperature (e.g. 4 °C) to avoid biological 
degradation of the sample.  
 1.1.2 Data preprocessing 
The acquired free induction decay (FID) data can be processed using ACD/NMR 
Processor (ACD/Labs, Toronto, Canada) in which 2x zero-filling and an exponential 
window function equivalent to 0.3 Hz line broadening is usually applied before Fourier 
transformation.  The spectra will be phased, baseline corrected, referenced to standard 
compound signal of a specific chemical shift, and exported as an ASCII file.  The ASCII 
file is imported into Excel and the spectral region from -0.02 ppm to 10 ppm is chosen for 





matNMR and MetaboLab can also be applied to process the raw FID data to visualize the 
spectra. 
1.1.3 NMR spectral signal assignment 
1D 1H NMR spectra are routinely acquired due to the high NMR sensitivity of the 
hydrogen nucleus.  However, the 1D spectra of samples containing complex mixture of 
metabolites can be congested due to the resonance appeared at the same chemical shift, 
making the resonance assignment a challenge.  2D homonuclear / heteronuclear 
correlation and J-resolved (JRES) experiments can be applied to alleviate the congestion 
of 1D spectrum.  Spectral resonance assignment is usually performed by searching 
chemical shift lists, for example, in HMDB, BMRB, Chenomx software (Chenomx Inc., 
Edmonton, Candada), and published literatures along with the analysis of specific J-
coupling patters of the metabolite spin systems.  Moreover, this process is more efficient 
now with the help of MetaboID28, a graphical user interface that offers comparison of 
experimental spectra with authentic metabolite spectra to guide assignment.   Usually, 
confident resonance assignment is achieved by combining the assignment of 1D 1H 
spectra along with the knowledge obtained from the 2D experiments of selected samples.  
1.2 Data processing and statistical analysis 
1.2.1 Data pretreatment  
Normalization is routinely used to account for the dilution effect of each sample as 
well as variation from different batch of measurement29. It is especially beneficial to urine 
sample data processing since urinary metabolite concentrations are dependent on the 





normalized to the creatinine level based on the assumption that the creatinine level is an 
indicator of the metabolite concentrations in urine.  However, creatinine normalization is 
questioned since factors such as muscle mass, age and gender can influence the normal 
urine creatinine level.   Another commonly used integral normalization method is the total 
area normalization, which assumes the total integral of all metabolites in a sample to be 
a constant throughout all samples.   However, this method is not applicable if drug 
metabolites also appeared in the sample.   Thus far, probabilistic quotient normalization 
(PQN) is brought to attention30. It calculates a most probable dilution factor (e.g. the 
median of the quotients) among all the metabolite variables which is then utilized to 
perform normalization of all variables in the sample.   
Scaling is a variable-based processing approach which is performed on the 
intensity of each metabolite across all samples, and influences the result of the 
multivariate analysis31.  It eliminates the bias towards high concentration metabolites in 
statistical analysis and the scaling method chosen is dependent on the specific statistical 
methods used in the analysis.  For instance, principal component analysis (PCA) which 
is performed on mean-centered data (e.g. metabolite variable mean is subtracted across 
all samples) is equivalent to performing PCA on a covariance matrix.  Whereas applying 
PCA on standardized variable (e.g. based on correlation matrix of the variables) requires 
the data to be scaled with unit variance scaling, dividing the intensity of each variable by 
the standard deviation of the variable intensities across all samples.  The advantages and 
disadvantages of various data pretreatment methods such as pareto scaling, log 





Table 1.1 Comparison of various data pretreatment methods as described by Van der burg et al32. 
 
 
1.2.2 Univariate analysis 
To compare each variable in the data containing two groups (e.g. benign and 
cancer), the student’s t test which relies on the comparison of the two-sample means is 
commonly used.  It requires each sample population to have a normal distribution, equal 
variance of the two populations and the data is independently sampled.   Welch’s t test 
can be applied to two sample populations with unequal variances.  For data contains 





difference between group means of each variable.   When the assumption of normal 
distribution is not met for the sample population, nonparametric analysis such as 
Wilcoxon rank sum test can be used to test the difference between two independent 
samples by comparing their medians.  Kruskal-Wallis one-way analysis of variance is the 
nonparametric equivalent of ANOVA comparing data with multiple groups.    
1.2.3 Multivariate analysis 
To account for the impact of all metabolites on the outcome of measurement (e.g. 
cancer and normal), multivariate analysis can be utilized.  Additionally, the multivariate 
model can be used to determine the metabolites contributing to the result as well as 
predicting the result.   
1.2.3.1 Unsupervised analysis 
Unsupervised analysis is the application of statistical models without the prior 
knowledge of the sample classification labels and it is usually the first step in data pattern 
exploration.   Principal component analysis (PCA) is representative of the unsupervised 
method and is commonly applied to reduce the dimensionality and examine the structure 
of the data set.  Scores plot is generated to assess the clustering of different samples, 
with the corresponding loadings plot demonstrating the variables accounting for the most 
variation in the specified principal component.   In addition, the cluster analysis, which is 
useful for the visualization of subgroups of multivariate data by partitioning methods or 





1.2.3.2 Supervised analysis 
In supervised analysis, information of sample class labels (e.g. disease and control) 
are also utilized in building the statistic models.   One commonly used supervised analysis 
is partial least squares discriminant analysis (PLS-DA) which maximizes the covariance 
between predictor variables (metabolite intensities from NMR measurement) and the 
response variables (e.g. the classes of each sample)33.  Namely, PLS-DA finds 
components (e.g. latent variables) in the predictor matrix that best predict the response 
variables.  It uses variable importance to projection (VIP) scores to demonstrate the 
contribution of each variable to the model, with metabolites VIP scores> 1 considered 
important in classification.  If class separation is not observed in scores plot of PLS-DA 
model, orthogonal partial least squares discriminant analysis (OPLS-DA) can be 
performed.  The OPLS-DA is a modification of PLS-DA model, in which the systematic 
variation of data that is not related to the response variable (e.g. sample class labels) is 
removed34.  It presents similar prediction ability to PLS-DA, and demonstrates improved 
model interpretability.35  Diagnostic parameters such as the number of misclassifications, 
cross-validated explained variation Q2 and the Area Under the Curve (AUC) of a Receiver 
Operating Characteristic (ROC) analysis are commonly used to indicate the model 
performance.   
1.2.3.3 Model validation 
To assess the predictive ability of the multivariate models, methods such as cross 
validation (CV), permutation or bootstrap can be conducted.  Cross validation involves 





classification models (e.g. PLS-DA), and the resulting model is used to predict the classes 
of the test set.  Depending on how the full data is partitioned into the two data sets, leave-
one-out CV and k-fold CV are commonly applied.  A permutation test can assess whether 
the classification based on true sample class is significantly better than classification 
based on randomly assigned sample class36.  Morever, bootstrap is a resampling method 
used for model validation37.  It generates a new data set the same size as the original by 
sampling with replacement from the original data set.  This new data set is used to build 
the prediction model, and the validation is applied on the original data set.   
1.3 Pathway analysis in disease biomarker discovery 
Metabolic pathway analysis is essential for the understanding of cellular processes 
of specific diseases, providing insight in the development of treatment methods.  After the 
identification of potential metabolite biomarkers, the particular pathway can be assessed 
using databases such as KEGG38 and HMDB39, or searching for literatures that contain 
pathway analysis of certain metabolite and disease.    The enzymes controlling the 
metabolite biomarker levels in the cell play a critical role in the development of the disease, 
thus, studies focusing on the knockdown of certain enzyme in the cell can be applied to 
test its impact on the biomarker level and promote understanding of mechanisms 







1. Barton, R. H.; Nicholson, J. K.; Elliott, P.; Holmes, E., High-throughput H-1 NMR-
based metabolic analysis of human serum and urine for large-scale epidemiological 
studies: validation study. International Journal of Epidemiology 2008, 37, 31-40. 
2. Fonville, J. M.; Maher, A. D.; Coen, M.; Holmes, E.; Lindon, J. C.; Nicholson, J. K., 
Evaluation of Full-Resolution J-Resolved H-1 NMR Projections of Biofluids for 
Metabonomics Information Retrieval and Biomarker Identification. Anal Chem 2010, 82, 
(5), 1811-1821. 
3. Schicho, R.; Nazyrova, A.; Shaykhutdinov, R.; Duggan, G.; Vogel, H. J.; Storr, M., 
Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of 
mice by (1)H NMR spectroscopy. J Proteome Res 2010, 9, (12), 6265-73. 
4. Want, E. J.; Masson, P.; Michopoulos, F.; Wilson, I. D.; Theodoridis, G.; Plumb, R. 
S.; Shockcor, J.; Loftus, N.; Holmes, E.; Nicholson, J. K., Global metabolic profiling of 
animal and human tissues via UPLC-MS. Nat Protoc 2012, 8, (1), 17-32. 
5. Beckonert, O.; Coen, M.; Keun, H. C.; Wang, Y.; Ebbels, T. M.; Holmes, E.; Lindon, 
J. C.; Nicholson, J. K., High-resolution magic-angle-spinning NMR spectroscopy for 
metabolic profiling of intact tissues. Nat Protoc 2010, 5, (6), 1019-32. 
6. Cheng, L. L.; Burns, M. A.; Taylor, J. L.; He, W.; Halpern, E. F.; McDougal, W. S.; 
Wu, C. L., Metabolic characterization of human prostate cancer with tissue magnetic 





7. Somashekar, B. S., magic angle spinning NMR based metabolic profiling of head 
and neck squamous cell carcinoma tissues. J Proteome Res 2011. 
8. Martineau, E.; Tea, I.; Loaec, G.; Giraudeau, P.; Akoka, S., Strategy for choosing 
extraction procedures for NMR-based metabolomic analysis of mammalian cells. Anal 
Bioanal Chem 2011, 401, (7), 2133-2142. 
9. Sellick, C. A.; Hansen, R.; Stephens, G. M.; Goodacre, R.; Dickson, A. J., 
Metabolite extraction from suspension-cultured mammalian cells for global metabolite 
profiling. Nat Protoc 2011, 6, (8), 1241-9. 
10. Ackerstaff, E.; Pflug, B. R.; Nelson, J. B.; Bhujwalla, Z. M., Detection of increased 
choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to 
malignant transformation of human prostatic epithelial cells. Cancer Res 2001, 61, (9), 
3599-3603. 
11. Gu, H.; Pan, Z.; Xi, B.; Hainline, B. E.; Shanaiah, N.; Asiago, V.; Gowda, G. A.; 
Raftery, D., 1H NMR metabolomics study of age profiling in children. NMR Biomed 2009, 
22, (8), 826-33. 
12. Assfalg, M.; Bertini, I.; Colangiuli, D.; Luchinat, C.; Schafer, H.; Schutz, B.; Spraul, 
M., Evidence of different metabolic phenotypes in humans. Proc Natl Acad Sci U S A 
2008, 105, (5), 1420-4. 
13. Lindon, J. C.; Holmes, E.; Nicholson, J. K., Metabonomics and its role in drug 






14. Martin, F.-P. J.; Sprenger, N.; Montoliu, I.; Rezzi, S.; Kochhar, S.; Nicholson, J. K., 
Dietary Modulation of Gut Functional Ecology Studied by Fecal Metabonomics. J 
Proteome Res 2010, 9, (10), 5284-5295. 
15. Yap, I. K. S.; Li, J. V.; Saric, J.; Martin, F.-P.; Davies, H.; Wang, Y.; Wilson, I. D.; 
Nicholson, J. K.; Utzinger, J.; Marchesi, J. R.; Holmes, E., Metabonomic and 
microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota 
modification in the mouse. J Proteome Res 2008, 7, (9), 3718-3728. 
16. Zhao, L.; Nicholson, J. K.; Lu, A.; Wang, Z.; Tang, H.; Holmes, E.; Shen, J.; Zhang, 
X.; Li, J. V.; Lindon, J. C., Targeting the Human Genome-Microbiome Axis for Drug 
Discovery: Inspirations from Global Systems Biology and Traditional Chinese Medicine. 
J Proteome Res 2012, 11, (7), 3509-3519. 
17. Dettmer, K.; Aronov, P. A.; Hammock, B. D., Mass spectrometry-based 
metabolomics. Mass Spectrom Rev 2007, 26, (1), 51-78. 
18. Somashekar, B. S.; Ijare, O. B.; Nagana Gowda, G. A.; Ramesh, V.; Gupta, S.; 
Khetrapal, C. L., Simple pulse-acquire NMR methods for the quantitative analysis of 
calcium, magnesium and sodium in human serum. Spectrochim Acta A Mol Biomol 
Spectrosc 2006, 65, (2), 254-60. 
19. Kovacs, H.; Moskau, D.; Spraul, M., Cryogenically cooled probes - a leap in NMR 






20. Lewis, I. A.; Karsten, R. H.; Norton, M. E.; Tonelli, M.; Westler, W. M.; Markley, J. 
L., NMR method for measuring carbon-13 isotopic enrichment of metabolites in complex 
solutions. Anal Chem 2010, 82, (11), 4558-63. 
21. Ye, T.; Mo, H.; Shanaiah, N.; Gowda, G. A.; Zhang, S.; Raftery, D., 
Chemoselective 15N tag for sensitive and high-resolution nuclear magnetic resonance 
profiling of the carboxyl-containing metabolome. Anal Chem 2009, 81, (12), 4882-8. 
22. Ye, T.; Zhang, S. C.; Mo, H. P.; Tayyari, F.; Gowda, G. A. N.; Raftery, D., C-13-
Formylation for Improved Nuclear Magnetic Resonance Profiling of Amino Metabolites in 
Biofluids. Anal Chem 2010, 82, (6), 2303-2309. 
23. Hoult, D. I., SOLVENT PEAK SATURATION WITH SINGLE-PHASE AND 
QUADRATURE FOURIER TRANSFORMATION. Journal of Magnetic Resonance 1976, 
21, (2), 337-347. 
24. Piotto, M.; Saudek, V.; Sklenar, V., Gradient-tailored excitation for single-quantum 
NMR spectroscopy of aqueous solutions. J Biomol NMR 1992, 2, (6), 661-5. 
25. Nguyen, B. D.; Meng, X.; Donovan, K. J.; Shaka, A. J., SOGGY: solvent-optimized 
double gradient spectroscopy for water suppression. A comparison with some existing 
techniques. J Magn Reson 2007, 184, (2), 263-74. 
26. Carr, H. Y.; Purcell, E. M., EFFECTS OF DIFFUSION ON FREE PRECESSION 






27. Chan, E. C.; Koh, P. K.; Mal, M.; Cheah, P. Y.; Eu, K. W.; Backshall, A.; Cavill, R.; 
Nicholson, J. K.; Keun, H. C., Metabolic profiling of human colorectal cancer using high-
resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) 
spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 
2009, 8, (1), 352-61. 
28. Mackinnon, N.; Somashekar, B. S.; Tripathi, P.; Ge, W.; Rajendiran, T. M.; 
Chinnaiyan, A. M.; Ramamoorthy, A., MetaboID: A graphical user interface package for 
assignment of (1)H NMR spectra of bodyfluids and tissues. J Magn Reson 2013, 226, 93-
9. 
29. Torgrip, R. J. O.; Aberg, K. M.; Alm, E.; Schuppe-Koistinen, I.; Lindberg, J., A note 
on normalization of biofluid 1D H-1-NMR data. Metabolomics 2008, 4, (2), 114-121. 
30. Dieterle, F.; Ross, A.; Schlotterbeck, G.; Senn, H., Probabilistic quotient 
normalization as robust method to account for dilution of complex biological mixtures. 
Application in 1H NMR metabonomics. Anal Chem 2006, 78, (13), 4281-90. 
31. Craig, A.; Cloarec, O.; Holmes, E.; Nicholson, J. K.; Lindon, J. C., Scaling and 
normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem 2006, 
78, (7), 2262-7. 
32. van den Berg, R. A.; Hoefsloot, H. C.; Westerhuis, J. A.; Smilde, A. K.; van der 
Werf, M. J., Centering, scaling, and transformations: improving the biological information 





33. Barker, M.; Rayens, W., Partial least squares for discrimination. Journal of 
Chemometrics 2003, 17, (3), 166-173. 
34. Stenlund, H.; Johansson, E.; Gottfries, J.; Trygg, J., Unlocking interpretation in 
near infrared multivariate calibrations by orthogonal partial least squares. Anal Chem 
2009, 81, (1), 203-9. 
35. Cloarec, O.; Dumas, M. E.; Trygg, J.; Craig, A.; Barton, R. H.; Lindon, J. C.; 
Nicholson, J. K.; Holmes, E., Evaluation of the orthogonal projection on latent structure 
model limitations caused by chemical shift variability and improved visualization of 
biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal Chem 2005, 
77, (2), 517-26. 
36. Golland, P.; Liang, F.; Mukherjee, S.; Panchenko, D., Permutation tests for 
classification. In Learning Theory, Proceedings, Auer, P.; Meir, R., Eds. Springer-Verlag 
Berlin: Berlin, 2005; Vol. 3559, pp 501-515. 
37. Shao, J., Bootstrap model selection. Journal of the American Statistical 
Association 1996, 91, (434), 655-665. 
38. Kanehisa, M.; Goto, S.; Hattori, M.; Aoki-Kinoshita, K. F.; Itoh, M.; Kawashima, S.; 
Katayama, T.; Araki, M.; Hirakawa, M., From genomics to chemical genomics: new 
developments in KEGG. Nucleic Acids Res 2006, 34, (Database issue), D354-7. 
39. Wishart, D. S.; Jewison, T.; Guo, A. C.; Wilson, M.; Knox, C.; Liu, Y.; Djoumbou, 
Y.; Mandal, R.; Aziat, F.; Dong, E.; Bouatra, S.; Sinelnikov, I.; Arndt, D.; Xia, J.; Liu, P.; 





Scalbert, A., HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res 







CHAPTER 2  




In metabolomics studies, conclusions are drawn based on the assumption that the 
expressed metabolic profiles will vary between sample states (e.g. disease and normal 
states).  Characterizing the concentrations of these differentially expressed metabolites 
is important for future application in clinical diagnosis of disease based on a threshold 
concentration level of the metabolite biomarkers.  Thus, sample preparation that 
enhances the detection of small molecular weight metabolites and facilitates their 
quantitation in nuclear magnetic resonance (NMR) spectroscopy is highly desired.  Blood 
serum is a commonly used clinical sample that contains both macromolecules such as 
proteins (e.g. albumin) and lipids (e.g. fatty acids) as well as small molecular weight 
metabolites.  In this study, we investigate the preparation of biofluids which contain 
macromolecules for NMR analysis by using human blood serum samples.   Principal 
component analysis was applied to assess the reproducibility of different preparation 
protocols, with serum/cold methanol 1:1 (v/v) followed by delipidation using cold 
chloroform producing the most efficient protein and lipid removal with high reproducibility.  





with deuterated methylene groups) incorporated with serum deproteination and 
delipidation can provide a quantitative reference for reliable estimates of metabolite 
concentrations in NMR analysis, which was confirmed by authentic metabolites spike-in 
experiments.  This sample preparation protocol results in improved metabolic profiling of 
serum metabolites and can be applied to quantitation of metabolites for NMR-based 
metabolomics.   
2.2 Introduction 
Nuclear magnetic resonance (NMR) spectroscopy has been employed widely in 
metabolomics research for its quantitative nature and broad coverage of 
metabolites, including those not amenable to mass spectrometry (e.g. non-ionizable 
metabolites).  NMR measurements exhibit higher reproducibility as compared with mass 
spectrometry, generating data with less variation that could be attributed to instrumental 
variation1.  Metabolic profiling using NMR can be applied to a variety of sample types 
including biofluids2, 3, 4, 5, 6, 7, 8, tissues9, 10, 11, 12  and cell lines13, 14, 15.  In particular, blood 
serum, equivalent to blood plasma with clotting factors removed16, is a commonly used 
biofluid for the biomarkers discovery of diseases17, 18.  The problem with analyzing blood 
serum lies in the fact that NMR resonances of macromolecules (e.g. proteins and lipids) 
in the serum mask the signals of metabolites in a single pulse NMR experiment, renders 
the quantitative analysis of metabolites impossible.   
Conventionally, for metabolic profiling of serum, T2 relaxation editing by Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence in an NMR experiment19, 20 is applied to 
attenuate signals from macromolecules with short T2 relaxation times.   However, signal 





pulse inaccuracies can lead to phase and baseline distortions21, resulting in inaccurate 
depictions of the metabolite concentration in the serum. 
Instead of CPMG NMR experiment of serum, sample preparation methods such 
as serum deproteinization by organic solvents or ultrafiltration can be used to retrieve 
information of the small molecular weight metabolites with improved data quality.  For 
example, protein precipitation by methanol/ethanol (1:1, v/v) and 
methanol/acetonitrile/acetone (1:1:1, v/v/v) yield a large number of extracted metabolites 
with good quality data in UPLC/MS measurement 22.  Using 100% methanol has also 
been shown to be very reproducible and effective in deproteination for metabolic profiling 
by LC/MS23.   However, the study of serum sample preparation for quantitative 
measurement of metabolites by NMR-based analysis is lacking.  One method uses 
ultrafiltration, whereby the serum is applied to a microcentrifuge filter with a specific 
molecular weight cutoff (e.g. 3 kDa) in order to filter out large molecular weight 
components.  Tiziani et.al24 have evaluated both deproteinization and ultrafiltration of 
serum for NMR analysis and proposed that ultrafiltration is more efficient at retaining 
metabolites after the sample processing and offers higher reproducibility.  However, 
ultrafiltration results in the loss of the hydrophobic fractions of the sample which is useful 
for lipidomics studies. Moreover, sample processing is time consuming due to multiple 
washing cycles needed to clean the glycerol in the microcentrifuge filter before applied to 
the serum.   
Targeted profiling was also reported for the quantitative analysis of 1D NMR data25 





were used to characterize metabolite concentrations in the sample.  But this approach 
requires the Chenomx software which is not readily available. 
Though various methods were reported for the serum preparation by MS analysis, 
there is no optimized and cost-effective preparation protocol available for metabolic 
profiling as well as metabolite quantification for NMR measurement.  Thus, serum 
preparation using organic solvents for the absolute quantitation of metabolites in 1D 1H 
NMR spectroscopy was evaluated in this study.  In addition, spike-in experiments with 
five authentic compounds (valine, alanine, glucose, tyrosine and phenylalanine) were 
performed, showing high accuracy of the protocol for serum metabolites quantification 
with TSP as an internal standard.   We demonstrate that the absolute quantification of 
serum metabolites can be achieved by introducing a known quantity of TSP prior to 
sample deproteinization and delipidation.  This protocol allows the utility of simple 1D 
single pulse NMR experiments for characterizing the concentration of metabolites and 
can be applied in the determination of cancer biomarker levels in serum or other 
proteinaceous biofluids (e.g. blood plasma and saliva). 
2.3 Experimental design  
2.3.1 Materials.  
All chemicals including alanine, valine, glucose, tyrosine, phenylalanine, 
potassium phosphate (monobasic, dibasic), Deuterium oxide (D2O), methanol,  ethanol, 
chloroform, 3-(Trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt (TSP) and human 





2.3.2 Protein removal and metabolite extraction.  
 To evaluate the optimal protein removal solvent conditions, serum were thawed 
and transferred to separate Eppendorf tubes with different volumes (300, 400, 500 and 
600 μL) and subject to the addition of  methanol (4 °C) or mixture of equal volume of 
methanol and ethanol (4 °C) in 1:1 and 1:2 ratios as shown in Table 2.1.  The solutions 
were vortexed for 30 s and incubated at   -20 0C for an hour.  Following the protein 
precipitation, the solutions were centrifuged at 10,000 RPM for 10 min and equal volume 
of the supernatant were obtained for further addition of chloroform (4 °C).  The mixtures 
were vortexed briefly and centrifuged (10,000 RPM, 10 min) in order to separate the 
aqueous and lipid fractions. The aqueous phases were transferred into glass vials for 














Table 2.1 Protocols for serum sample preparation. 
Each protocol was tested with different serum quantity represented by experiment 1-4.  All volumes were 
at μL scale. 
 
 
2.3.3 TSP as an internal standard for serum extraction.   
To test the effectiveness of TSP as an internal standard for serum extraction, two 
methods were compared using 400 μL of serum separately. In the first method, 50 μL 
TSP solution (1.42 M) was added to the serum before methanol (4°C) 1:1 (v/v) 
Protocol a Serum MeOH CHCl3 
1:1:1 
(v/v/v) 
Exp. 1 300 300 300 
Exp. 2 400 400 400 
Exp. 3 500 500 500 
Exp. 4 600 600 600 
Protocol b Serum MeOH CHCl3 
1:2:2 
(v/v/v) 
Exp. 1 300 600 600 
Exp. 2 400 800 800 
Exp. 3 500 1000 1000 
Exp. 4 600 1200 1200 





Exp. 1 300 300 300 
Exp. 2 400 400 400 
Exp. 3 500 500 500 





processing, whereas in the second method, serum protein was removed first by reaction 
with methanol (4 °C), then 50 μL of TSP was added to the supernatant. Both samples 
were then extracted with chloroform and the aqueous layer was obtained and dried using 
SpeedVac.  
2.3.4 Metabolite spike-in experiment. 
 In order to test the validity of serum sample preparation for the quantification of 
metabolites, spike-in experiments were conducted by the addition of five metabolites in 
varying weights with TSP as the internal standard. Specifically, a metabolite stock solution 
was made so that 0.109, 0.091, 0.566, 0.057 and 0.062 mg of valine, alanine, glucose, 
tyrosine and phenylalanine respectively will present in every 100 uL of the stock solution. 
Equal volume of the serum sample (400 uL) was taken and each was separately spiked 
with a known and different amount of the metabolite stock solution (40, 60, 80 and 100 
uL).  Control sample was prepared using 400 uL of serum without spike-in.  We then 
added 50 uL of TSP solution (1.42 M) to each sample and the samples were all diluted to 
the same volume (550 uL) by the addition of MilliQ water.  The resulting samples were 
then subject to protein precipitation by methanol (4 °C) in 1:1 (v/v) and further extraction 
as described in protocol a.  Mixture of 100 uL of metabolite stock solution and 50 uL of 
TSP solution (1.42 M) were prepared to provide the theoretical quantification of the spiked 
in metabolites.   All experiments described above were performed in triplicate. 
2.3.5 NMR experiments and data processing.   
The dried aqueous extracts were reconstituted in 540 μL of phosphate buffer (0.1 
M, pH 7.2, prepared in D2O).  Samples were vortexed briefly and transferred to 5 mm 





capillary containing 60 μL of TSP (1.16 M, prepared in D2O) was used to provide an 
external reference signal. 
All measurements were performed at 298 K on a Bruker AVANCE 500 MHz 
spectrometer (Bruker BioSpin, Karlsruhe, Germany) equipped with a BBI probe.  For each 
1D 1H spectrum, a single pulse experiment with a 45° flip angle and water suppression 
were used.  Experiments were conducted with a 17 ppm spectral width, 5 s recycle delay 
and 256 transients each containing 32K data points.  The acquired free induction decay 
(FID) data were processed using ACD/NMR Processor 12.01 (ACD/Labs, Toronto, 
Canada) in which 2x zero-filling and an exponential window function equivalent to 0.3 Hz 
line broadening were applied before Fourier transformation.  The spectra were phased, 
baseline corrected, referenced to TSP at 0 ppm, and exported as an ASCII file.  The 
ASCII files were imported into Excel and the spectral region from -0.1 ppm to 10 ppm was 
chosen for subsequent analysis.  Spectral alignment was performed in SpecAlign and the 
spectral data were normalized to the integral of TSP signal.  Additionally, water (4.6-5.15 
ppm) and methanol (3.33-3.4 ppm) intensities were set to zero. 
The signal assignment of the 1D spectra were confirmed by the 2D 1H–1H total 
correlation spectroscopy (TOCSY) NMR experiments.  The data were acquired with the 
MLEVPRTP pulse sequence (from the Bruker pulse program library) using a spin-lock 
mixing time of 70 ms.   A spectral width of 8503.40 Hz was used in both dimensions, and 
256 t1 increments were acquired, each containing 2048 complex data points.  The number 
of transients per t1 increment was 64, and the relaxation delay was set to 5 s.  All 2D 





For quantitative NMR, it is necessary to re-establish the magnetization of nuclei in 
between FID acquisition and the application of a next pulse, which is affected by the 
setting of relaxation delay in the experiment.  This parameter is usually determined at 5 
times the longest longitudinal proton relaxation time T1 in the sample and also is 
dependent on the flip angle of the excitation pulse.  To ensure sufficient relaxation delay 
was given in the 1D 1H experiment, the relaxation time constant T1 was measured for all 
protons in a serum extract.  An inversion recovery experiment with water suppression 
was applied and 17 variable delays ranging from 0.0001 to 10 s were utilized.  Peaks 
from non-overlapped regions were integrated and subjected to T1 calculation. 
2.3.6 Statistical analysis.   
To reduce the dimensionality and examine the structure of the data set, principal 
component analysis (PCA) was performed on the mean-centered data set of serum 
extraction using protocols a, b and c.  Scores plots were generated to assess the 
clustering of samples in different extraction conditions.  The statistical tests were 
performed in Matlab (R2010a). 
2.3.7 Quantitation of serum metabolites.   
Metabolite signal integrals were determined from characteristic peak regions of the 
five metabolites presented in the stock solution.  Especially, chemical shift region from 
3.1650-3.2615 ppm was used to calculate the glucose integral since glucose level from 
both α and β anomeric formations were demonstrated in this region. TSP and lactate 
integrals were obtained as quantitation references.  Furthermore, we calculated the 





from the 400 μL serum control samples to estimate the observed quantity of the spiked 
in metabolites.   





 where the No. of proton from the metabolite peak are the ones that contribute to the 
determination of the peak integral.   
2.4 Results and Discussion 
2.4.1 TSP as an internal quantitative reference for serum preparation and analysis 
by NMR.   
Absolute quantification of metabolites in NMR analysis requires the addition of an 
internal standard that neither interacts with the sample system nor appears at a chemical 
shift that overlaps with other metabolite signals26.   Formate has been reported as a 
quantitative reference for serum analysis by NMR27. However, the varied endogenous 
quantity of formate in serum of different individuals renders this compound inappropriate 
for quantitative analysis.  External quantitative reference can also be used to avoid 
reaction with the samples by putting the external reference compound in a coaxial 
capillary which then inserted into the NMR tube28.  The drawback of using an external 
reference is that the loss of metabolites during sample processing cannot be revealed 
due to reference to a fixed compound concentration in the capillary.   
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TSP is a common chemical shift reference for NMR measurement due to its non-
reactivity with metabolites and resonance in the high field region isolated from metabolite 
signals in the spectrum.  It also serves as a quantitative reference for urinary metabolite 
quantification29 in 1H NMR study.  However, as for an internal quantitative reference 
compound, TSP cannot be added to samples containing high protein levels such as tissue 
and blood serum with no further processing of the mixture due to the interaction of TSP 
with proteins30.  We tested serum sample preparation by the addition of a known quantity 
of TSP before continuing to deproteinization and delipidation to assess whether this 
sample processing can remove the effect of the interaction between TSP and the 
macromolecules.   As illustrated in Figure. 2.1, no loss of TSP was observed during 
protein removal, indicating the effect of weak binding of TSP with serum proteins were 
removed, which can be explained by the high efficiency of protein removal, causing the 
dissociation of the bound TSP.  Thus, TSP can be used as an internal standard to monitor 
the recovery of extracted metabolites. 
 
Figure 2.1 TSP as a quantitative reference for serum metabolite quantification. 
1D 1H NMR spectra of selected regions.  Red spectrum: from a sample with the addition of TSP before 
protein removal by cold methanol.  Black spectrum:  from a sample with the addition of equal quantity of 
TSP after protein removal.   The peak area of alanine is the same since equal amount of serum was used 





To ensure quantitative NMR analysis, the proper relaxation delay need to be given 
that allows the magnetization to relax to equilibrium before the execution of a next pulse.  
Thus, longitudinal magnetization recovery experiments were conducted to characterize 
the T1 relaxation time of various metabolites.  The calculated T1 values (data not shown) 
proved the efficacy of using a relaxation delay of 5 s when a 45° pulse was used in our 
NMR experiment.  
2.4.2 Comparison of serum preparation protocols. 
To assess the efficiency of protein removal and metabolite extraction, Figure 2.2 
demonstrated the resulting NMR spectra after serum preparation by protocols a, b and 
c.   Protocol a applies 100% methanol for protein removal with serum to organic solvent 
volume ratio of 1:1, whereas protocol c utilizes 1:1 (v/v) mixture of methanol and ethanol 
in replacement of the pure methanol.  Similar metabolite features were observed for 
protocols a and c, with slightly reduced peak intensity of histidine in protocol c.  Protocol 
b assessed protein precipitation with serum to methanol in 1:2 (v/v), yielding broad peaks 
around 0.7-0.9 and 1.1-1.3 ppm due to the insufficient removal of lipids and proteins.  This 
result is predictable based on the observation during sample processing where protein 
was further extracted out with a layer in between solvents after the addition of chloroform 







Figure 2.2 Metabolic profiles based on different extraction protocols. 
Representative 1D 1H NMR spectra from samples processed by protocol a, b and c.  The green regions 
highlight signals originate from large molecular weight components. 
 
2.4.3 PCA analysis of serum sample preparation methods. 
NMR data of different sample preparation protocols a, b and c were normalized to 
TSP integral and subject to multivariate statistical analysis PCA to assess the data 
structure and protocol reproducibility.  As shown in Figure 2.3, the triplicate samples of 
protocol a grouped together tightly, symbolizing good reproducibility with the difference 





However, the lack of reproducibility of samples of protocol b indicates that the volume 
ratio of serum to organic solvents is crucial for the variation in the data.   Interestingly, the 
addition of more organic solvent does not necessarily improve the deproteination and 
delipidation efficiency of serum as demonstrated in the comparison of samples from 
protocol a and b.   Protocol c demonstrated a separation trend along PC 1 and the 
clustering of triplicate samples, which is in agreement with the study of the preparation of 
plasma for metabolic profiling by UPLC-MS22, showing good reproducibility for 
methanol/ethanol deproteinization.   
 
Figure 2.3 PCA scores plot of 1D 1H NMR data of serum samples prepared with protocols a, b and 
c. 
 
2.4.4 Spike-in experiment proved the accuracy of quantitative analysis. 
NMR peak integrals were obtained for the five spiked-in metabolites in samples 
containing the 400 μL of serum (control samples) and samples consisting of equal volume 





from the controls yields the observed quantity due to the amount of metabolite stock 
solution added.   Theoretical spiked-in metabolite levels were obtained by calculating the 
metabolite peak integrals of the 100 μL stock solution prepared with the addition of equal 
quantity of TSP (50 μL ,1.42 M).   All integrals were further characterized relative to TSP 
and lactate in each spectrum since equal concentration of lactate and TSP were present 
across all samples.  Figure 2.4 shows the plot of the spiked-in metabolite quantity 
observed by NMR with respect to the theoretical quantity added.  Great linearity was 
observed with R2 > 0.99 for all the spiked metabolites, which reflected the high accuracy 







Figure 2.4 Calibration curves obtained for the authentic metabolites spike-in experiment. 
Observed metabolite quantity in the y-axis represents the spiked-in metabolite quantity resulted from 
subtracting the observed quantity of the control samples from the true sample metabolite concentrations in 
NMR spectra.  The high R2 values demonstrate the validity of the sample preparation for the absolute 
quantification of metabolites.  Error bars represent the standard deviation of three replicate sample 
measurements with the same amount of spiked in metabolites. 
 
2.5 Conclusion 
Quantitation of serum metabolites by metabolic profiling in NMR is commonly 
applied in studies such as biomarker discover of specific diseases.  However, due to the 





1D 1H NMR spectrum, CPMG NMR is often used to suppress the broad peaks to facilitate 
the quantification of small molecular weight metabolites.  The quantitative result is 
arbitrary due to the simultaneous T2 relaxation processes of both the macromolecules 
and the metabolites.  And the signal to noise no longer serves as an accurate 
measurement of the metabolite concentrations. Thus, to obtain the absolute quantitative 
information of serum metabolites, we propose deproteination and delipidation of serum 
with TSP as an internal standard for NMR-based metabolic profiling (Figure 2.5).  Our 
result shows that serum proteins can be effectively removed by 1:1 (v/v) mixture with cold 
methanol and further delipidation by the addition of cold chloroform in volume ratio of 1:1 
relative to serum.   The sample should be left in -20 °C for at least 30 min to allow fully 
protein precipitation.  It is proved by the spike-in experiments that the absolute 
concentration of metabolites can be obtained with respect to TSP due to the fact that a 
known quantity of TSP was added and any loss of metabolites during the sample 
processing will also be reflected in the loss of TSP.  This serum sample preparation 
method allows the application of 1D 1H single pulse NMR experiment with water 
suppression, which demonstrates accurate quantification of metabolites, thus it can be 
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CHAPTER 3  
Optimized urinary metabolite separation into two-phase solvent 
system for improved signal assignment in NMR-based metabolomics 
 
3.1 Abstract 
Urine metabolic profiling is increasingly used for disease and drug metabolism 
research by nuclear magnetic resonance (NMR) spectroscopy which has the unique 
advantage of nonselective and nondestructive detection of metabolites.  However, the 
constituent complexity of urine imposes challenges to NMR-based urine metabolomics 
studies with difficulties arising from accurate signal assignment of peaks from the highly 
congested 1H NMR spectra.  In this study, we demonstrate an approach to overcome the 
spectral crowding issue by employing a two-phase solvent extraction 
(methanol/chloroform/water extraction) on urine before NMR analysis for the purpose of 
separating urinary metabolites into either polar or non-polar phases.  Measurement of 
each phase individually is then hypothesized to yield simplified metabolic profiles of urine, 
leading to improved spectral assignment.  Extraction conditions were compared with 
varying water volumes and water pH in 2:1 (v/v) chloroform/methanol mixtures.  Our 
results demonstrate that the efficiency of metabolite extraction was dependent on water 
volume while independent of water pH, and the protocol for optimal distribution of 
metabolites into the two phases was to use a minimal water volume for extraction.  This 





urinary metabolites for subsequent analyses and applications such as cancer biomarker 
identification.  
3.2 Introduction 
Characterizing low molecular weight metabolites 1, 2 in biofluids (e.g. serum, 
plasma, urine, amniotic fluid, cerebrospinal fluid, saliva and other digestive fluids) 3, 4, 5, 6, 
tissues 7, 8, 9, 10 and cells 11, 12, 13 have been extensively studied to get insights of the 
perturbation to an organism which may have been caused by diseases 14, aging 15 or 
external stimuli (e.g. drug treatment) 16, 17, 18, 19, 20.  Among these sample types, urine, the 
metabolic end product that reflects the physiological conditions of the organism, is a 
favored choice both in clinical screening and metabolic phenotype research for its 
noninvasive nature and ease of collection.  One of the analytical techniques for 
metabolomics study, nuclear magnetic resonance (NMR) spectroscopy has been 
employed widely for its quantitative nature and broad coverage of metabolites, including 
those not amenable to mass spectrometry (e.g. non-ionizable metabolites).  NMR 
measurements exhibit high reproducibility as compared with mass spectrometry, 
generating data with less variation that could be attributed to instrumental variation.  
Commonly one-dimensional 1H NMR spectra are sufficient and acquired for subsequent 
statistical analysis including both univariate and multivariate methods.  Metabolite signal 
assignment is usually performed by searching chemical shift lists, for example, in HMDB 
21, BMRB 22, Chenomx software (Chenomx Inc., Edmonton, Candada) and published 
literatures 23, 24 combined with the analysis of specific J-coupling patters of the spin 
systems of the compound.  Moreover, this process is more efficient now with the help of 





with authentic metabolite spectra to guide assignment.  However, the complexity of 
biological sample components, in particular urine, which contains a large variety of 
compounds (e.g. aromatic, aliphatic compounds, amino acids, sugars, and osmolytes) 
existing in a broad range of concentrations result in complicated NMR spectra and thus 
spectral assignment is a significant challenge.  One approach to cope with sample 
complexity is separation of metabolites prior to NMR analysis.  Multiple studies using 
various separation techniques have been reported for NMR-based metabolomics.  For 
example, two-phase solvent extraction of tissues 26 and cells 27, 28 for the assessment of 
differences in metabolic phenotype between normal and malignant states of cancer, and 
high performance liquid chromatography (HPLC) 29 and solid phase extraction (SPE) for 
urine purification in drug metabolite analysis 30.  In particular, extraction methods such as 
MeOH/H2O, ACN/H2O, MeOH/CHCl3/H2O and ACN/CHCl3/H2O have been compared for 
liver tissue by NMR and LC-MS analysis 31.  The results of Beltran and coworkers 
indicates MeOH/H2O treatment followed by MeOH/CHCl3/H2O extraction is the most 
efficient protocol, with the extract NMR spectrum having an enhanced signal to noise ratio 
(S/N) as compared with the raw tissue spectrum.  A comparison of various extraction 
methods on mammalian cells for NMR analysis also demonstrated the efficiency and 
reliability of MeOH/CHCl3/H2O extraction of intracellular metabolites 11.  Critically, there is 
little data currently available that describes the extraction of urine, which would be 
expected to analogously reduce the complexity and improve the sensitivity for NMR-
based metabolomics. 
We propose a two-phase extraction protocol of urine for metabolic profiling by 





and enhance the ability of spectral assignment.  Our results suggest that the integration 
of a two-phase urine extraction protocol in the standard sample preparation for 
metabolomic analyses may be beneficial for the identification of otherwise difficult to 
assign NMR signals.   
3.3 Experimental design  
3.3.1 Materials and urine sample.   
All chemicals including potassium phosphate (monobasic, dibasic), sodium 
carbonate, sodium bicarbonate, Deuterium oxide (D2O), methanol, chloroform and 3-
(Trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt (TSP) were purchased from 
Sigma/Aldrich (Milwaukee, USA).  All the solutions were prepared in water of MilliQ 
quality.  Urine samples were collected based on a protocol approved by the Institutional 
Review Board, and urine of 10 different individuals were pooled together and stored at  
-80 °C.  This pooled urine sample was utilized in extraction.  Since individual sampling 
error was eliminated by using this pooled sample, the main source of variation is expected 
to be caused by the various extraction protocols. 
3.3.2 Two-phase urinary metabolite separation.  
 Three different protocols (Table 3.1) were used to optimize the efficient separation 
of metabolites in two-phase solvent systems.  Before the separation, urinary proteins 
were removed by adding cold methanol to 500 µL of urine in a 1:1 (v/v) ratio and keeping 
the mixture at -20 C for at least 30 min.   Following the protein precipitation, the mixture 
was centrifuged (10,000 rpm, 10 min), and the supernatant was transferred into glass 





CHCl3 and CH3OH were added at a 2:1 (v/v) ratio to each of the triplicate sample, mixed 
thoroughly and kept at room temperature for about 60 min.  Two conditions of extraction 
water were compared in which either the water volume or pH were chosen as variables 
as described below.  
Extraction H2O – varied volume.  The amount of water added played an important role in 
determining the polarity of the extraction solvent system.  In this protocol, 120 µL, 90 µL 
and 60 µL of water were added separately as shown by protocol 1, 2 and 3 to study the 
effect of water volume on the extraction efficiency.  
Extraction H2O – varied pH.  This experiment was performed to compare the extraction 
efficiency of metabolites at multiple pH of extraction water.  Typical simple carboxylic 
acids have an approximate pKa = 5, while primary amine groups have an approximate 
pKa = 9.  In this study, H20 buffered at pH 3, 7 and 10 were chosen for the purpose of 
decreasing the aqueous solubility of the carboxylate and amino containing metabolites 
through protonation or deprotonation, respectively, thereby reducing the congestion of 
metabolite signals in the polar phase NMR spectra.  Extraction water with specified pH 
was obtained by using 0.1 M phosphate (pH 3, 7) or carbonate (pH 10) buffered solution.  
The water volume was held at 60 µL for all extractions involving buffered H2O (protocol 










Table 3.1 Extraction protocols of urine samples. 
Protocols 1, 2 and 3 test the effect of varied volume of H2O, whereas protocols 4, 5 and 6 compare the 
impact of varied pH of H2O on the extraction. 












1: 2: 0.4 
1: 2: 0.3 
3 500 µL 300 µL 600 µL 60 µL 1: 2: 0.2 
4 500 µL 300 µL 600 µL 60 µL pH 3 1: 2: 0.2 
5 500 µL 300 µL 600 µL 60 µL pH 7 1: 2: 0.2 
6 500 µL 300 µL 600 µL 60 µL pH 10 1: 2: 0.2 
* Urine was treated with 500 µL cold methanol and kept at -20 C for 1 h.  Samples were then centrifuged 
and the supernatant was dried in SpeedVac. 
 
Regardless of the extraction protocol, after the addition of H2O, samples were 
vortexed and centrifuged at 10,000 RPM for 10 minutes.  The polar and non-polar phases 
were collected separately.  The non-polar extracts were evaporated to dryness under a 
stream of N2 and all extracts were then subjected to SpeedVac drying.  Dried samples 
were stored at -80 oC until NMR measurements.   
3.3.3 NMR spectroscopy.  
 Both polar and non-polar extracts were reconstituted separately in 560 μL of 
phosphate buffer (0.1 M, pH 7.2, prepared in D2O) containing TSP ([TSP] = 1.5 mM) as 
the NMR reference signal.  Samples were vortexed and centrifuged briefly with 550 μL of 





All measurements were performed at 293 K on a Bruker AVANCE 500 MHz 
spectrometer (Bruker BioSpin, Karlsruhe, Germany) equipped with a 5 mm TXI SB probe.  
For each 1D 1H spectrum, a single pulse experiment with a 45o flip angle and water 
suppression were used.  Experiments were performed with a 14 ppm spectral width, 3 s 
recycle delay and 128 transients each containing 32K data points.  The acquired free 
induction decay (FID) data were processed using ACD/NMR Processor 12.01 (ACD/Labs, 
Toronto, Canada) in which 2x zero-filling and an exponential window function equivalent 
to 0.3 Hz line broadening were applied before Fourier transformation.  The spectra were 
phased, baseline corrected, referenced to TSP at 0 ppm, and exported as an ASCII file.  
The ASCII files were imported into Excel and the spectral region from -0.02 ppm to 10 
ppm was chosen for subsequent analysis.  The intensity of each spectrum was 
normalized to the TSP signal.  Additionally, water (4.6-5.15 ppm) and methanol (3.33-3.4 
ppm) intensities were set to zero.  All 1D spectra were aligned based on the variable-
reference interval correlated shifting (vr-icoShift) method 32.   
To further reduce the signal overlap and compare metabolic patterns of polar and 
non-polar extracts, two-dimensional 1H–1H total correlation spectroscopy (TOCSY) NMR 
experiments were performed on the extracted sample processed according to protocol 3.  
2D TOCSY spectra were acquired with the MLEVPRTP pulse sequence (from the Bruker 
pulse program library) using a spin-lock mixing time of 70 ms.  A spectral width of 7002.80 
Hz was used in both dimensions, and 256 t1 increments were acquired, each containing 
2048 complex data points.  The number of transients per t1 increment was 64, and the 






3.3.4 Statistical analysis.   
In order to reduce the dimensionality and examine the structure of the data set, 
principal component analysis (PCA) was performed on the mean-centered data set.  
Scores plots were generated to assess the clustering of samples in different extraction 
conditions, with the corresponding loadings plot examined to identify the variables 
accounting for the most variation in the specified principal component.  The statistical 
tests were performed in Matlab (R2010a). 
3.4 Results and Discussion  
3.4.1 Complexity of NMR spectra of urine.  
 NMR-based metabolomics of urine have been applied to diverse fields of research 
such as the study of metabolic alterations with drug treatments to delineate the adaptive 
response to drugs associated with toxicity33, identification of urinary metabolic biomarkers 
for early detection of prenatal disorders34, autosomal dominant polycystic kidney 
disease35 and lung cancer36, and assessment of the effect of physical exercise protocols 
on the metabolic changes in urine37.  The complexity of 1D 1H NMR spectra of urine is 
both beneficial in terms of the rich information content available, and challenging with 
respect to resonance assignment, where the objective would be to extract the full 
information content.  Spectral complexity of biofluids can be alleviated by chemoselective 
isotope tagging of carboxyl containing metabolites and amino metabolites, with the limit 
of detection to μM level.  For example, 15N tagging of carboxyl containing metabolites with 
15N-ethanolamine38 and 13C formylation of amino metabolites using 13C formic acid 39.  
These methods greatly help in the identification and quantification of only certain class 





metabolites of the other classes.  Due to the various steps involved for the tagging 
reactions followed by quantification using 2D 1H-13C/15N HSQC, the routine application 
on the urine is limited for high throughput metabolic profiling by NMR-based analysis. To 
address the spectral complexity of urine, we performed MeOH/CHCl3/H2O extraction with 
the goal of separating polar and non-polar metabolites into a two-phase solvent system, 
which was reported to yield high extraction efficiency of tissues as compared with other 
extraction methods31.  Individually, the polar and non-polar phases would then be 
expected to yield two simplified 1H NMR spectra, potentially aiding in the resonance 
assignment.  We explored the MeOH/CHCl3/H2O extraction with different volumes and 
pH of H2O since the extraction efficiency and reproducibility may be affected by the pH 
and polarity of the extraction solvent system.  This extraction method is easy to perform 
and results in a broad coverage of metabolites that may otherwise lost with other 
processing methods.     
3.4.2 Sample pre-processing and optimization of the two-phase solvent systems.   
 Before the extraction, cold MeOH was used for urinary protein removal with a 1:1 
volume ratio of MeOH to urine, which reduces the effective concentration of water, 
resulting in less hydration of the protein in the urine.  To examine the impact of the protein 
removal step, a control experiment without the protein removal was performed where the 
native urine was centrifuged and the supernatant was collected for NMR analysis.  No 
distinct differences of the metabolite resonances were observed in the comparison of the 
native urine with the cold MeOH processed urine, which reveals that the addition of 
methanol to urine will not result in the loss of any urinary metabolites.  Moreover, the 





MeOH/CHCl3/H2O extraction by reducing the protein content at the interface of the two 
layers.  Thus all the urine samples were subjected to cold methanol treatment prior to 
extraction.  Notably, methanol treatment for protein removal is reported to be highly 
effective for tissue 31 and serum 40 sample analysis.   
3.4.3 NMR analysis of non-polar and polar solvent phases. 
1H NMR spectrum of non-polar part (Figure 3.1 a) obtained with protocol 1(1:2:0.4) 
showed peaks corresponding to only few metabolites since most of the metabolites were 
retained in the polar part (Figure 3.1 b).  However, non-polar part (Figure 3.2 a) obtained 
with protocol 2 (1:2:0.3) showed the presence of considerable amount of metabolites.  
This clearly indicates that reducing the water content in the solvent mixture enhances the 
chances of distributing the metabolites into the non-polar phase. Therefore, with further 
reduction of water ratio in protocol 3 (1:2:0.2), non-polar part (Figure 3.3 c) showed >90% 
of relatively non-polar metabolites whereas highly polar metabolites retained in the polar 
extract (Figure 3.3 b).  In Figure 3.3, selected regions in the black dotted squares highlight 
metabolites that are dominant in either the non-polar (blue spectrum) or polar (red 
spectrum) phase.  For instance, the citrate signal (2.5 – 2.7 ppm) only appeared in the 
polar phase, as might be expected of a highly polar small molecule such as citrate which 
contains a hydroxyl and three carboxyl groups.  In contrast, metabolites such as aromatic 
amino acids (phenylalanine, hippurate), modified aromatic amino acids 
(phenylacetylglycine, phenylacetylglutamine), branched chain amino acids (valine, 
leucine, isoleucine) and other relatively non-polar metabolites (dimethylamine, succinic 
acid) can be easily extracted into the non-polar part, leaving the majority of polar 





result in better separation of polar and non-polar metabolites but is limited due to practical 
difficulties in separating the two solvent layers.  In 1H NMR spectrum of urine, usually the 
spectral range between 3-4.5 ppm is highly complex in which CH peaks of amino acids 
appear along with other metabolites.  
 
 
Figure 3.1 Representative 1D 1H NMR spectra of native urine and extracts using protocol 1 








Figure 3.2 Representative 1D 1H NMR spectra of native urine and extracts using protocol 2 







Figure 3.3 Representative 1D 1H NMR spectra of native urine and extracts. 
Native urine (black), polar extract (red) and non-polar extract (blue), resulting from the extraction using 
protocol 3 (MeOH/CHCl3/H2O volume ratio of 1: 2: 0.2).  Spectral regions from 0.7 to 4.5 ppm and 6.5 to 
8.7 ppm were shown.  Black dotted regions highlight resonances that had higher abundance in either the 
polar or non-polar phase extract.  Enlarged spectra at chemical shifts around 1.20-1.25 ppm and 6.65-6.70 
ppm were shown in the yellow dotted squares. 
 
By achieving metabolites separation using protocol 3 and measuring the 2D 1H-1H 
correlation spectrum of non-polar and polar extracts separately, the spectral complexity 
of urine can be greatly reduced.  The simplified spectrum of each phase will aid in the 
assignment of 2D NMR spectrum of urine where hundreds of cross-peaks appear.  For 
example, we have measured 1H-1H TOCSY of protocol 3 non-polar and polar parts 
separately and compared with TOCSY of native urine, in which great reduction in spectral 
complexity can be observed.   In the overlay of 2D 1H-1H TOCSY spectra of the polar 





separated well based on the polarity.  Non-polar metabolites such as isoleucine and 
alanine were present exclusively in the non-polar extract whereas polar metabolites such 
as lysine and glutamic acid were more abundant in the polar extract. 
 
 
Figure 3.4 2D 1H-1H TOCSY spectra of neat urine and extracts. 
Neat urine (black spectra on the left), overlaid spectra of polar (blue spectrum) and non-polar (red spectrum) 
extracts utilizing protocol 3 with MeOH/CHCl3/H2O (v/v/v) of 1: 2: 0.2.  Expansion of the chemical shift 
regions (0.5-4.5 ppm and 6.3-9.5 ppm) are shown separately in order to highlight signals visible in one 
phase versus the other. Abbreviations: Ile, isoleucine; Lac, lactate; Gln, glutamine; Lys, lysine; Cit, citric 
acid; Leu, leucine; Ala, alanine; Pro, proline; Tyr, tyrosine; Tau, taurine; DTC, 4-deoxythreonic acid; U1, 2-
furoylglycine; U2, histamine; U3, 1-methylnicotinic acid; U4, 5-hydroxysalicylic acid; U5, o-Cresol; U6, 
acetophenone; U7, phenylacetylglutamine; U8, p-cresol sulfate; U9, butanone; U10, suberate; U11, 1-





To examine the influence of water volume on the extraction, we assessed the 
metabolite separation in the two-phase solvent system by quantifying several signals from 
protocol 1, 2 and 3.  The mean ± standard deviation of integrals from four metabolite 
signals in both the non-polar and polar extracts are shown in Figure 3.5, clearly 
demonstrating an increase of the metabolite quantity in the non-polar phase as a function 
of decreased water content utilized in the solvent mixture.  These results reveal that the 
addition of minimal water into MeOH:CHCl3  solvent systems facilitates the partition of 
metabolites into the non-polar phase more readily, distinguishing these molecules from 
the metabolites that are consistently more soluble in the polar phase.  Therefore, we 
propose 1:2:0.2 (MeOH:CHCl3:H2O v/v/v) two-phase solvent system  for better separation 
of urinary metabolites.  
 
Figure 3.5 Bar plots of mean integrals calculated for metabolite signals in both the polar and non-
polar phases with different water volumes in extraction. 





3.4.4 PCA analysis.   
PCA was performed on the NMR data of both non-polar and polar extracts 
obtained with different protocols to assess the reproducibility of triplicate measurements 
as well as the effect of water content on metabolite separation in the two-phase solvent 
system.  A clear separation between non-polar and polar extract NMR metabolic profiles 
was observed along principal component (PC) 2 (Figure 3.6 a).   Except for the polar 
extract of protocol 2, all the other triplicate measurements grouped together closely, 
revealing good reproducibility for each extraction approach.  Largest group separation of 
non-polar and polar extracts along PC 1 was observed for samples obtained from protocol 
3, revealing that protocol 3 is best suitable for metabolites separation.  Loadings plot 
along PC 1 (Figure 3.6 b) represents the metabolites that contribute to the largest 
variance of the data (68.87%).  Examination of the loadings along PC 2 (Figure 3.6 c) 
showed that creatinine, citrate and lysine were crucial for the segregation of the two 






Figure 3.6 Principal component analysis of urinary metabolite extracts with varied water volume. 
The scores plot (a) displays the relationship between samples with the proportion of variance explained by 
principal component (PC) 1 and PC 2.  Each point represents a single spectrum. Both the polar extracts 
(filled circles) and non-polar extracts (empty circles) are separated from each other along PC 2, indicating 
difference in the polar and non-polar extracts NMR spectra.   Loadings plots show the resonances that 
contribute to the variance of the specific principal component.  (b) PC 1 loadings.  (c)  PC 2 loadings. 
 
To assess the effect of water pH on the metabolites separation, PCA was also 
performed on NMR spectra of both the non-polar and polar phases obtained by 1:2:0.2 
extraction in which the pH of water varied from 3-10.  A separation of non-polar and polar 
phase profiles was observed in the scores plot in Figure 3.7, symbolizing a difference in 
metabolic profiles of the two phases.  The clustering of the non-polar extract triplicates 





more on the water volume rather than the water pH for consistent extraction of urinary 
metabolites. 
 
Figure 3.7 PCA scores plot of samples extracted with different water pH. 
 
3.5 Conclusions 
Assignment of metabolites in NMR spectra is crucial for subsequent statistical and 
biological interpretation of data.  Urine, a common biofluid utilized in metabolomic studies, 
poses significant challenges because of the highly congested NMR spectra, hindering the 
correct assignment of metabolites present in the biological system.  In this report, we have 
introduced the methanol/chloroform/water extraction of urinary metabolites before NMR 
measurement with the aim of partitioning metabolites with different chemical properties 
into polar and non-polar solvent systems.  The results indicate that using minimal water 
(MeOH:CHCl3:H2O, 1:2:0.2, v/v/v) for extraction allows more metabolites to be extracted 





extraction solvents can be used for better handling of the separation of the two phases in 
considering that the same extraction solvent ratio 1:2:0.2 was kept, as well as the 
proportional urine volume taken for the extraction.  Moreover, the simplified metabolite 
patterns of the polar and non-polar extracts shown in the 2D TOCSY experiment is 
expected to further enhance metabolite assignment capabilities.  We believe that this 
method of analyzing the effect of two-phase solvent extraction applied to urine with the 
specific intention of simplifying NMR spectra, providing a means for improved signal 
assignment.  Further studies on the de-convolution of NMR spectral peaks is necessary 
for better signal identification in NMR-based metabolomics studies in order to reduce 
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CHAPTER 4   
Prostate cancer diagnosis using NMR-based metabolic profiling of 
serum 
4.1 Abstract 
Prostate cancer (PCa) is the most common cancer of aging men and is usually 
diagnosed at an advanced stage by invasive biopsy tests.  To alleviate patients’ pain with 
the biopsy test, we propose the metabolic profiling of blood serum as a relatively non-
invasive approach to facilitate the early detection of PCa. This is based on the hypothesis 
that the expressed metabolic profiles will be different between cancerous and benign 
states.  We performed serum metabolic profiling of 25 benign and 25 PCa samples using 
1H nuclear magnetic resonance (NMR) spectroscopy.  Both univariate wilcoxon rank sum 
tests and multivariate partial least squares discriminant analysis (PLS-DA) showed a 
consistent result that 2-hydroxyvalerate, glycine, fructose, choline and creatine can be 
used as potential biomarkers that distinguish between the benign and PCa state.  This is 
a pioneer study of the metabolic alterations in serum samples that characterize PCa by 
NMR metabolic profiling, which can facilitate the development of clinically useful 







Prostate cancer (PCa) as the most severe form of prostate related disease, is among the 
common cancers detected in aging men, with an estimated 238,590 men diagnosed and 
29,720 cancer-related deaths in the United States in 2013 according to the PCa statistics 
of National Cancer Institute.   
To diagnose PCa, a screening test is performed which include digital rectal exam 
(DRE), prostate-specific antigen (PSA) / PSA Density (PSAD) test and transrectal 
ultrasound (TRUS).  If the test results suggest cancer, a prostate biopsy needs to be 
performed, which is the only way to confirm the presence of PCa.   However, the DRE 
result is subjective to the empirical knowledge of doctors and is only effective for detecting 
abnormalities close to the rectum, while omitting other areas of the prostate1.  In addition, 
PSA has low specificity for PCa detection2, and other prostate diseases (e.g. BPH) also 
demonstrate an elevated PSA level in the serum3.  Even for patients with PSA levels less 
than the normal threshold value (3-4 ng/mL), the presence of PCa is not uncommon4.   
These controversial test results lead to a higher probability of unnecessary biopsy tests.  
Therefore, to alleviate the pain and avoid complication caused by the biopsy test, it is 
imperative that non-invasive biomarkers be identified that will reliably differentiate cancer 
and normal states of the prostate.   
Metabolic profiling techniques have been increasingly applied to characterize the 
small molecular weight metabolites as the determinant of disease and have laid the 
framework for the new diagnostic approach of various types of cancer5-9.  Different 
metabolite levels reflect the pathophysiological condition of the organism and metabolites 





pathways, providing insight in treatment methods to minimize the dysfunctional enzymatic 
processes.  Metabolic profiling typically relies on gas chromatography (GC) and liquid 
chromatography (LC), in conjunction with mass spectrometry (MS) and nuclear magnetic 
resonance (NMR).  In particular, MS enjoys high sensitivity (~fmol) and is capable of 
identifying hundreds of metabolites in a single sample.  Various studies have reported the 
metabolomics approach in the diagnosis of prostate cancer on different sample types 
using MS.  For example, Sreekumar et.al proposed several metabolites (e.g. sarcosine), 
as metabolite biomarkers for metastatic prostate cancer10.  Besides, Zhou et.al identified 
plasma lipids (e.g. phosphatidylethanolamine, ether-linked phosphatidylethanolamine 
and ether-linked phosphatidylcholine)11 that can differentiate PCa from control plasma 
samples by MS-based lipid profiling.  Moreover, Zhang et.al reported urinary metabolites 
(e.g. 2-oxoglutarate and indolylacryloyglycine) as biomarkers for prostate cancer 
detection12.  However, these MS-based analysis requires complex sample preparation, 
quantification cannot be easily applied to clinical tests since it requires the addition of the 
isotope labeled form of each specific metabolite and offers limited reproducibility.  In 
addition, little is known about the metabolic profiles of blood serum samples that may 
differentiate PCa and benign states, given that the serum samples are easily accessible 
at clinics.   
As another commonly used analytical techniques for metabolomics study, nuclear 
magnetic resonance (NMR) spectroscopy has been employed for its quantitative nature 
and broad coverage of metabolites, including those not amenable to mass spectrometry 
(e.g. non-ionizable metabolites).  NMR measurements exhibit high reproducibility as 





attributed to the instrumental variation.   Thus in this study, we investigated NMR-based 
metabolic profiling of serum samples for the early detection of PCa.  The challenge 
remains the identification and quantification of a large number of metabolites in the 
proteinaceous serum samples and determining significant metabolic differentiation 
between pathophysiological states.  Therefore, serum deproteinization and delipidation 
were performed in order to obtain accurate quantification of serum metabolites in NMR-
based metabolic profiling.  Both univariate (e.g. Wilcoxon rank sum tests, ROC analysis) 
and multivariate statistical analysis (e.g. PCA, PLS-DA) were applied to determine the 
differential metabolites.  This study highlights the effectiveness of NMR-based serum 
metabolic profiling for the early detection of PCa. The identification of five differential 
metabolites provides insight for future application in clinical diagnosis. Moreover, further 
understanding of the biochemical pathways of these metabolites will lead towards 
effective, personalized therapeutics.  
4.3 Materials and Methods 
4.3.1 Prostate serum sample collection 
25 biopsy positive and 25 biopsy negative serum samples were collected 
according to the sample collection protocols approved by the University of Michigan 
Medical School Institutional Review Board for Human Subject Research.  
4.3.2 Sample preparation for NMR metabolic profiling 
To remove the interference of the broad NMR resonances of macromolecules on 
the metabolic profiles, serum proteins need to be removed.  Therefore in our study, we 





mixing each serum sample with the cold methanol in 1:1 (v/v) for the protein precipitation.  
The mixture was left at -20 °C for 30 min.  We then centrifuged the sample at 10,000 RPM 
for 10 min and obtained the supernatant for further metabolite extraction.  150 µL of cold 
chloroform was added into the supernatant for lipid removal.   The sample was then 
vortexed and centrifuged in order to separate the aqueous and lipid extracts.  We dried 
the aqueous extract using a vacuum concentrator and stored the dried sample at -20 °C 
before NMR metabolic profiling.  Due to the limited sample availability which results in 
low concentration of metabolites, we used a solid state MAS-NMR instrument equipped 
with a nanoprobe as the measurement approach for improved S/N.  It is more beneficial 
than a traditional solution state NMR since it employs a sample holder which requires less 
volume (~40 µL) than it is needed with a regular 5 mm NMR tube for a solution state NMR 
experiment (~500 µL).  
4.3.3 1H MAS NMR spectroscopy 
All metabolic profiling were conducted on a Varian Inova 600 MHz MAS NMR 
spectrometer equipped with the gHZ nanoprobe that enables the measurement of 
samples with small solvent volumes.  The aqueous extract of each serum sample was 
reconstituted in 50 µL of phosphate buffer (0.1 M, prepared in D2O) and 45 µL was used 
for NMR measurement at 298 K.  1D 1H NMR experiments at 2500 Hz spinning rate and 
water saturation were performed in which 16,000 data points were collected in 128 scans.  
We processed the data using ACD/NMR Processor 12.01 (ACD/Labs, Toronto, Canada) 
in which 2x zero-filling and an exponential window function equivalent to 0.3 Hz line 
broadening were applied before Fourier transformation.  We then phased the spectrum, 





data was exported as ASCII files and subject to further data processing such as 
normalization and spectral alignment in Matlab (R2010a) as described below.  
Excluding TSP, methanol, water and chloroform resonances, total area 
normalization was performed on each sample to eliminate the systematic variation 
caused by different sample dilutions.  Afterwards, all spectra were aligned based on the 
vr-icoShift method13.  
4.3.4 Multivariate modeling 
To investigate the metabolites differentiating biopsy negative from biopsy positive 
serum, multivariate analysis was performed on the above processed data.  First, the 
unsupervised principal component analysis (PCA) model was utilized to reduce the 
dimension of data as well as visualizing the data structure.  We performed Monte Carlo 
cross validation with autoscaling to determine the optimal number of latent variables (LVs) 
to build the partial least squares discriminant analysis (PLS-DA) classification model.  
After building the PLS-DA model using the optimal LVs, variable importance in projection 
(VIP) score of each variable was calculated based on variable weights of LV1 and ranked 
in descending orders.  Variables with VIP score>1 were selected as significant peaks that 
can differentiate biopsy negative from biopsy positive serum samples.  All statistical 
analysis was performed in Matlab and SPSS software.    
4.3.5 Univariate analysis 
We performed a two-sided Wilcoxon rank sum test to compare the concentration 
of each metabolite in the benign and PCa groups to obtain the p-values to test the 
difference in these two groups.  In order to identify altered metabolite signals, we also 





of benign samples and scaled by the standard deviation of benign for that particular 
metabolite. Moreover, metabolites identified as significant in differentiating the benign and 
PCa samples were quantified by integration and plotted in a receiver operating 
characteristic (ROC) curve to visualize the predictive ability of this metabolite at different 
sensitivity and specificity levels.  The area under the curve (AUC) represents the 
discriminatory ability of this metabolite as the potential biomarker, with values close to 1 
as a better classification.  
4.4 Results and discussion 
Diseases associated with the prostate, including benign prostatic hyperplasia (BPH), 
prostatitis, and cancer are among the leading diagnosed conditions among men.  Current 
screening techniques for prostate cancer (PCa) are restricted to serum Prostate-Specific 
Antigen (PSA) levels and digital rectal examination (DRE).  Unfortunately, high levels of 
serum PSA will not uniquely identify prostate cancer, and coupled with the high false-
positive PSA testing rates, invasive biopsy procedures are required for disease 
confirmation14.  Serum as a commonly used sample type in clinical practice, contains a 
wide variety of biochemical components which reveals the pathophysiological state of the 
organisms.  Our study aims to generate a biomarker multiplex panel in relatively non-
invasive serum samples that will indicate with greater sensitivity and specificity the 
development of PCa, thus alleviating the dependence on PSA and biopsy tests.  We 
propose the utilization of 1H NMR metabolic profiling approach due to its great potential 
in reporting on the current metabolic state, where changes at the genetic and protein 
expression levels on disease onset are amplified downstream in the metabolites. These 





provide insight on the treatment methods based on the specific metabolic pathway 
analysis. 
4.4.1 1H NMR metabolic profiles  
In general, NMR-based metabolomics studies on serum samples were carried out using 
CPMG spectra, which gives information from small molecules by filtering out signals from 
macromolecules (proteins, lipoproteins, glycoproteins)15.  However, CPMG spectra don’t 
provide quantitative accuracy16.  In order to get quantitative information of serum 
metabolites, in the present study, we extracted aqueous metabolites from serum samples 
and 1H NMR metabolic profiling was carried out on twenty-five benign and twenty-five 
PCa serum samples.  Two representative 1H NMR spectra obtained from aqueous 
extracts of a benign and a PCa serum sample were shown in Figure 4.1.  The chemical 
shift assignment of metabolites was conducted based on literature reports, metabolite 
data bases (e.g. HMDB, BMRB), and confirmed by resonance correlations in the acquired 
2D 1H-1H TOCSY spectrum.  More than twenty-two metabolites were identified both in 
benign and PCa serum samples (Figure 4.1) including amino acids, sugars, choline 
containing compounds and other organic acids.  To detect overall changes in the 1H signal 
intensities of benign and PCa samples, mean and standard deviation was calculated for 
benign group for each binned chemical shift variable.  Furthermore, each benign and PCa 
sample was centered by the benign mean and scaled by the benign standard deviation.   
Z-scores plot of the 1H signals deviation from benign state for both groups was shown in 
Figure 4.2, with several metabolite variables in the PCa samples showing altered 






Figure 4.1 Representative 1D 1H NMR spectra of benign and PCa serum metabolite extracts. 
The pound sign represents methanol peak whereas the star represents chloroform peak. 
 
 
Figure 4.2 z-scores plot for each metabolite variables of the benign and PCa samples.  






4.4.2 Statistical analysis 
To determine the differential metabolites between benign and PCa samples, 
unsupervised PCA was performed.  Before this multivariate statistical analysis, unwanted 
chemical shift regions were removed from the 1H spectra and the resultant data was 
normalized to the total intensity.  Since the PCA score plot didn’t show clustering of the 
two groups, a supervised PLS-DA was performed to maximize the covariance of 
metabolite signals with the sample class information (e.g. benign and PCa).  The optimal 
number of components, namely the number of latent variables (LVs) to build the PLSDA 
model was selected based on the Monte Carlo cross validation (MCCV) approach.  In 
contrast to the commonly used leave one out cross validation, MCCV leaves out a large 
part of data (e.g. leave out 30% of the data randomly in each round of MCCV analysis) 
as the test set to determine the prediction error rate.  The number of LVs yielding the 
smallest error rate was retained as the optimal number of LVs for PLSDA model 
development.  In our case, 500 MCCV was performed on the full data set, resulting in 2 
LVs as the optimal parameter to build the PLSDA model.   The scores plot and LV 1 
loadings plot of PLSDA was shown in Figure 4.3.  Despite the overlap of a few benign 
with PCa samples, separation of the two groups was observed in the scores plot, 
indicating the difference of the metabolic profiles of these samples.  The loadings plot of 
LV1 revealed increased level of branched chain amino acids, lactate, alanine, glutamine, 
glycine, choline and tyrosine, and decreased levels of glucose.  Signals were ranked 
according to their contribution to the PLSDA model using variable importance to 
projection (VIP) scores as shown in Table 4.1.   And the top five VIP ranked metabolites 






Figure 4.3 Scores and loadings plot based on PLSDA model performance. 
 
In addition to the multivariate statistical analysis, we also performed univariate 
statistical analysis (Wilcoxon rank sum test) on binned NMR data (1732 bins; bin size 
0.004 ppm), in which binned dataset with P < 0.05 was considered statistically significant. 
Not surprisingly, the observed statistically significant binned datasets is corresponded to 
the high VIP ranked metabolites (Table 4.1).  Further, mean and standard deviation of 
peak intensities for 2-hydroxyvalerate, glycine, fructose, choline and creatine were 
calculated using the chemical shift range of 1.314 to 1.354 ppm, 3.564 to 3.573 ppm, 
3.589 to 3.609 ppm, respectively.   The levels of these five metabolites were shown in 
Figure 4.4.  Among these five metabolites, only 2-hydroxyvalerate was significantly 
decreased and other four metabolites were significantly increased in PCa compared to 
benign serum.  To address the diagnostic potential of these differential metabolites, ROC 
analysis was performed individually for each metabolite and the corresponding AUC 
values were included in Table 4.1.  The diagnostic performances of these key differential 
metabolites are enhanced comparing with the PSA based test to discriminate PCa from 







Figure 4.4 Metabolite levels of the potential biomarkers in distinguishing between benign and PCa 
serum samples.   
Integrals were measured after total area normalization. 
 
 
Table 4.1 Collection of potential metabolite biomarkers of PCa. 
Signals ranked according to their VIP scores calculated from PLSDA model of LV1, p values resulting from 
Wilcoxon rank sum tests and AUC values of each metabolite. 
 
Metabolite VIP rank p value  AUC 
2-hydroxyvalerate  1 0.007 0.725 
Glycine 2 0.002 0.762 
Fructose 3 0.012 0.755 
Choline 4 0.008 0.784 






4.4.3 Metabolic alterations and signal transduction pathways 
Increased choline level is observed in PCa serum, which is associated with the 
breakdown of membrane phospholipid during malignant transformation of human 
prostatic epithelial cells18.  The alteration of choline is related to increased choline kinase 
activity that catalyzes choline to form phosphorylcholine with the consumption of ATP as 
well as the increased phospholipase activity that breaks down phosphotidylcholine to 
reform choline19.  These choline signaling pathways provide a rationale for a variety of 
applications.  For example, the inhibition of phospholipase (PLCy1) showed a 50% 
reduction in phosphocholine levels and can be used as a therapeutic target to block the 
cancer cell invasion and metastasis20. Moreover, 11C labeled choline has been applied as 
a radiopharmaceutical for positron emission tomography (PET) imaging to detect the local 
recurrence of prostate tumor21.   
Elevated levels of glycine was found in PCa serum, which was also reported in 
colorectal cancer22, head and neck cancer studies by NMR23.  The reliance on glycine for 
the proliferation of cancer cells was studied by means of gene expression of metabolic 
enzymes24, which reveals the enhanced expression of glycine biosynthesis enzymes in 
cancer cells.  Glycine is then incorporated into purine biosynthesis in cancer cell 
proliferation.  Our observation of increased creatine level in PCa serum may further 
indicate the alteration in energy metabolism of PCa patients.  2-hydroxyvalerate is 







We presented a novel metabolic study of serum using NMR-based profiling and 
identified several serum metabolites that can distinguish between benign and PCa 
patients.  Further validation of these potential metabolite biomarkers will be assessed 
over a large group of independent serum bio-specimens that are linked to 
clinical/pathology data. The altered metabolite level of these potential biomarkers 
provides great insight into the diagnosis of PCa as well as understanding the mechanism 
of PCa development through the specific biochemical pathway analysis.  This noninvasive 
serum metabolite biomarker panel may be potentially applied in screening of prostate 
cancer rather than limiting on the analysis of only the protein level (e.g. PSA) in serum.  
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CHAPTER 5  
NMR-based metabolomic profiling of urine nominates a signal 
biomarker panel for prostate cancer detection 
 
5.1 Abstract 
Detection of prostate cancer and distinguishing indolent versus aggressive forms 
of the disease is a critical clinical challenge.  The current clinical test is circulating PSA 
levels, which faces particular challenges in cancer diagnosis in the range of 4 – 10 ng/mL.  
Thus, a concerted effort towards building a noninvasive biomarker panel has developed.  
In this report, the hypothesis that NMR-derived metabolomic profiles measured in the 
urine of biopsy-negative versus biopsy-positive individuals would nominate a selection of 
potential biomarker signals was investigated.  1H NMR spectra of urine samples from 317 
individuals (111 biopsy-negative, 206 biopsy-positive) were analyzed.  A double cross-
validation PLS-DA modeling technique was utilized to nominate signals capable of 
distinguishing the two classes.  It was observed that after variable selection protocols 
were applied, a subset of 29 variables produced an AUC value of 0.94 after logistic 
regression analysis, while a ‘master list’ of 18 variables produced an ROCAUC of 0.80.   
As proof of principle, this study demonstrates the utility of NMR-based metabolomic 
profiling of urine biospecimens in the nomination of prostate cancer specific biomarker 






 Prostate cancer (PCa) is a disease that is estimated to be diagnosed in 238,590 
American men in 2013.  As a disease that typically occurs late in life, morbidity rates are 
low, especially given that there are forms of PCa malignancies that progress slowly.  
However, this presents a critical challenge to clinicians responsible for diagnosing and 
delivering prognoses since there is a current lack of clinical standard for predicting 
aggressive versus indolent forms of PCa.  The current clinical screening test is circulating 
serum Prostate Specific Antigen (PSA), however there are several issues associated with 
the PSA test1, 2, 3.  First is the low specificity of PCa, with multiple conditions associated 
with prostate swelling also resulting in elevated PSA levels.  Second is the sensitivity, 
with a clinically challenging range of 4-10 ng/mL difficult to diagnose as aggressive or 
indolent PCa.  As a result of these drawbacks, there have been recent reports suggesting 
that PSA testing has potentially done greater harm than good, primarily through 
overdiagnosis and the associated deleterious treatment side-effects4.  Thus, there is a 
critical requirement for clinically relevant screening tests capable of distinguishing 
aggressive and indolent forms of PCa with high specificity. 
  Biomarker discovery in relation to PCa continues to be an active area of research, 
and several recent reviews are available on the topic5, 6, 7, 8.  In many cases, biomarkers 
are discovered via an ‘omics’ approach, and thus there are candidate molecules 
representative of the genetic, protein, and metabolite levels.  The standard clinical test 
relies on circulating PSA levels, a protein that exists both in free and bound forms.  Thus 
in an effort to refine PSA testing both fractions have been included, with the amount of 





protein markers include -methylacyl-CoA racemase10 and AGR211.  Several peptides 
have also been nominated in urine as potential biomarkers of PCa, although care must 
be taken in sample collection and preparation12.  Several genes have been identified as 
PCa specific biomarkers, including PCA3 and the TMPRSS2:ERG gene fusion.  These 
have been detected in both tissue13 and urine14, 15, 16, and are thus attractive from the 
standpoint of development of noninvasive PCa biomarker panels.  In addition, DNA 
methylation17 and single nucleotide polymorphisms18 have been explored as urinary PCa 
markers.  Finally, metabolite biomarkers have been identified, with a recent 
comprehensive profiling study nominating several metabolites capable of distinguishing 
biopsy-negative and biopsy-positive urine sediment samples19.  Among the metabolites 
highlighted, sarcosine has received particular attention and several validation studies 
have since been reported with a clear consensus on biomarker status yet to be 
established20, 21, 22, 23. 
Metabolomic based investigations are attractive in terms of sample processing, 
where for example extensive protein purification assays or gene amplification procedures 
are not necessary.  Additionally, perturbed metabolite levels represent the end product of 
genetic dysfunction, and thus may be utilized to trace through the metabolic pathways to 
the dysfunctional enzymatic process.  Analytical platforms commonly employed for 
metabolomic studies include mass spectrometry (MS) and nuclear magnetic resonance 
(NMR), each possessing complementary strengths and weaknesses24.  Mass 
spectrometry based PCa metabolomic investigations of urine samples have been 
extensively reported, however there is a noticeable absence of NMR based reports.  NMR 





this report addresses the hypothesis that urinary 1H NMR profiles of biopsy-negative 
individuals will differ from biopsy-positive individuals, and the differential signals may be 
assembled into a biomarker panel for PCa detection. 
5.3 Materials/Methods 
5.3.1 Materials  
3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP), D2O, and potassium 
phosphate (monobasic, dibasic) were obtained from Sigma/Aldrich (Milwaukee, USA) 
and used as received.  All water was of MilliQ purity. 
5.3.2 Urine specimens & sample treatment 
Samples were collected post-digital rectal exam (DRE).  Samples were centrifuged 
immediately upon receipt, and the supernatant and sediments were stored separately.  
All NMR experiments were performed on urine supernatants.  Urine samples were stored 
at -80 °C until used.  NMR sample preparation involved aliquoting 450 µL of neat urine 
with 50 µL of phosphate buffer (pH 7.2) containing TSP as a chemical shift and 
concentration reference ([phosphate] f = 100 mM, [TSP]f = 3.7 mM).  The sample was 
subjected to centrifugation for 1 minute to remove insoluble material and transferred to a 
5 mm NMR tube.  All samples were prepared on the day of measurement.    
5.3.3 NMR Spectroscopy 
All NMR measurements were performed on a Bruker AVANCE™ 900 MHz (Bruker 
Biospin, Germany) with a TCI cryoprobe operating at a 1H frequency of 889.79 MHz at 





32K data points, with a spectral width of 16 ppm and recycle delay of 2 s.  WATERGATE 
water suppression was utilized. 
The raw FID data were imported in ACD/Labs NMR Processor, and were subjected 
to zero filling to 64K points and exponential multiplication equivalent to 0.3 Hz line 
broadening prior to Fourier transformation.  Each spectrum was manually phase and 
baseline corrected and referenced to the TSP signal at 0 ppm prior to exporting the data 
as an ASCII file.  All further processing, including statistical analyses, was performed in 
Matlab R2010b. 
 Spectra were normalized using the Probabilistic Quotient Normalization method, 
which has been shown to effectively reduce dilution variation28.  The reference spectrum 
for normalization was selected according to a closeness index29, a scaled correlation 
coefficient which identifies the spectrum most similar to all other spectra.  In order to 
reduce data variation arising from small chemical shift variation, spectral alignment was 
performed using the variable reference alignment method30.  Prior to statistical modeling, 
the data set was binned (bin size = 0.005 ppm) in order to reduce the number of variables 
to a computationally manageable number, and scaled.  Two scaling procedures were 
tested:  each variable had the mean subtracted and scaled to unit variance31, and each 
variable had the mean of the biopsy-negative samples subtracted followed by division by 
the standard deviation of the biopsy-negative samples.  In the latter scaling method, 





5.3.4 Statistical Analyses 
5.3.4.1 Model development  
A double cross validation (2CV) PLS-DA method32 was used in order to develop 
models capable of classifying biopsy-negative versus biopsy-positive individuals.  Briefly, 
the full dataset was first randomly divided into a calibration and test set.  The calibration 
set is utilized to develop a PLS-DA model according to traditional single cross validation 
(1CV), whereby the data is randomly divided into training and validation sets.  The training 
sets are used to generate PLS-DA models which are used to predict the classifications of 
the validation set.  All prediction errors are stored and the PLS-DA model with optimal 
prediction performance is selected.  After 1CV is performed on the calibration data, an 
optimal number of PLS components is identified and a final model is generated using the 
full calibration data set.  Finally, this model is used to predict the classifications of the test 
set and all prediction errors are stored.  The entire procedure is repeated several times, 
generating a series of different, but related, models.   
 Model performance was measured by three parameters, the number of 
misclassifications, a prediction error measure (Q2), and the Area Under the Curve (AUC) 
of a Receiver Operating Characteristic (ROC) curve.  Reference distributions for the null 
hypothesis of the three parameters were generated by performing 2CV on the full dataset 
after class label permutation.  Significant values are expected only when using the correct 
class labels, which are directly comparable to the null hypothesis distributions using the 





In this work, null hypothesis distributions for the three performance parameters 
were generated by performing 500 class label permutations, with 20 models developed 
for each permutation (i.e. 2CV was performed 20 times for each permutation).  For each 
permutation, 70% of the samples were randomly selected as the calibration set and the 
average value of the number of misclassifications, Q2, and AUC was calculated over the 
20 models.  The double cross validation procedure was then repeated 1000 times using 
the correct class labels, resulting in a collection of 1000 different, but related models.  
Both the distribution over all 1000 models and mean ± standard deviation of the three 
performance parameters are reported.    
5.3.4.2 Variable selection  
Three methods were explored for their ability to select variables strongly 
contributing to the PLS-DA models developed.  The first method involved ranking 
variables according to their absolute regression coefficient value calculated for each PLS-
DA model.  The frequency with which a variable appeared in the top 2% ranking was 
calculated across the models.  Variables that appeared in the top 2% in at least 50% of 
the models were considered important.  The second method involved the calculation of 
the variable importance to projection (VIP) score of each variable for all models 
calculated33.  The variables were ranked according to their VIP score, and a frequency 
was calculated in the same fashion as for the regression coefficient analysis.  The final 
method involved a more rigorous calculation of variable importance, known as 
competitive adaptive reweighted sampling (CARS), described by Li and coworkers34.  
Briefly, in this method a series of PLS-DA models, built upon a data subset selected by 





exponentially filtered and subjected to competitive weighting according to their ability to 
affect model performance.  A subset of variables is finally realized after selecting the 
model with the best performance characteristics (lowest prediction error).  The CARS 
method was applied to each model developed using 100 Monte Carlo samplings, and 
variables that were selected in at least 50% of the models were considered important.    
 Logistic regression analysis was performed using the selected variables with ROC 
curves generated and AUC values calculated.   
Univariate statistics were performed on the selected variables as an alternative 
measure of variable importance.  The Wilcoxon U-test was used to compare the 
normalized intensities of the selected variables, and all p-values were subjected to the 
Bonferroni correction for multiple comparisons. 
5.4 Results and Discussion 
Prostate cancer diagnosis continues to be a difficult clinical challenge, and new 
diagnostic techniques based on biomarker detection in non-invasive samples are under 
active research.  Urine is perhaps is the most attractive noninvasive biospecimen in terms 
of simplicity of collection, and several reports have discussed potential prostate cancer 
biomarkers detectable in urine supernatant or sediment19, 35.  To date, metabolite 
biomarkers have been investigated by mass spectrometry, with a noticeable lack of NMR 
based metabolomic investigations for urinary prostate cancer detection.  Representative 







Figure 5.1 900 MHz 1H NMR spectra of a selected biopsy-negative (blue) and biopsy-positive (red) 
urine supernatant sample. 
Spectra were referenced to TSP, PQN normalized, and aligned.  Inset: expansion of chemical shift region 
from 0.7 to 3.0 ppm, with vertical scale increased by a factor of 10.  Selected assignments of common PCa 
biomarkers are given: Crn – creatinine; CCC – choline containing compounds region; Cit – citrate; Ala – 
alanine; Lac – lactate. 
 
Urine is a particularly challenging biospecimen to work with in terms of biomarker 
discovery since there is large compositional variability depending on diet, time of 
collection, gender, and medication taken by the patient36, 37.  To overcome this challenge, 
large sample cohorts are necessary and multivariate statistical modeling is essential in 
identifying reliable candidate biomarkers.  Principal components analysis (PCA) is a 
common technique utilized in metabolomic studies, however PCA failed to separate 
biopsy-negative from biopsy-positive profiles (data not shown).  Thus a PLS-DA approach 





5.4.1 Auto-scaled data 
As argued by Westerhuis and coworkers32, model parameters reporting on 
performance characteristics are often difficult to judge without an idea of how the model 
operates under the null hypothesis.  Thus, they proposed performing permutation 
analyses as part of the modeling process to generate expected parameter distributions 
for the same data set assuming the null hypothesis is true.  The expected number of 
misclassifications, AUC values, and Q2 values after permutation of class labels are 
summarized in Figure 5.2 and Table 5.1.  Taking 30% of the data as the test set resulted 
in 96 samples comprising the test set.  The number of misclassifications and AUC values 
were determined to be 48 ± 2 and 0.49 ± 0.04, respectively, indicating as expected that 
the modeling performed no better than random in class prediction.  Importantly, the 
parameter distributions are vastly different when 2CV PLS-DA is applied utilizing the 
correct class labels.  Improvement of all parameters was observed (decreased number 
of misclassifications, increased Q2, and increased AUC, p < 0.0001 in all cases), 
suggesting the models were capable of identifying signals important in distinguishing 






Figure 5.2 Distributions of the number of misclassifications, Q2, and AUC after 2CV-PLS-DA 
modeling of the full NMR data set. 
The data was auto-scaled prior to modeling.  1000 models were generated using the correct class labels 
(red), and 500 models using permuted class labels were generated (blue).  In all cases, the distributions 
using the correct class labels were significantly different compared to the permuted models (p < 0.0001 for 








Table 5.1 Summary of model performance parameters for 2CV-PLS-DA modeling based on NMR 
data that was auto-scaled. 
Using the original labels, 1000 models were generated while 500 models were generated using the 
permuted labels.  All values are reported as mean ± standard deviation.  In the case of permuted data, 
mean parameter values were first calculated over the 20 models per label permutation followed by mean 
± standard deviation calculation over all 500 permutations.   
 Data set Misclassification Q2 AUC 
Original 
Labels 
Full 33 ± 4 -0.06 ± 0.16 0.69 ± 0.05 
CARS 20 ± 4 0.35 ± 0.08 0.86 ± 0.03 
Reg Coeff 28 ± 4 -0.01 ± 0.14 0.76 ± 0.04 
VIP 28 ± 4 0.01 ± 0.14 0.76 ± 0.04 
Permuted 
Labels 
Full 48 ± 2 -0.68 ± 0.24 0.49 ± 0.03 
CARS 48 ± 3 -1.6 ± 0.4 0.49 ± 0.04 
Reg Coeff 47 ± 3 -2.8 ± 0.9 0.49 ± 0.04 
VIP 47 ± 3 -2.9 ± 0.8 0.49 ± 0.01 
 
Application of 2CV PLS-DA resulted in a collection of 1000 models, each built 
using a randomly selected subset of samples from the full data set.  Thus, while each 
model is different, all models are related.  Identification of a single model would facilitate 
the examination of standard PLS-DA parameters such as latent variable loadings and 
scores in order to gain information on the variables contributing to the class separation.  
In the case where many similar models are generated, selection of a single ‘best’ model 
is not trivial32.  Therefore, variable selection methods were applied to each model 
generated, resulting in a collection of important signals over all models.  Variable selection 
continues to be an important problem in multivariate analyses34, 38, and without a clear 





value based on PLS loadings and thus reports on the importance of each variable in 
contributing to the overall model33.  Since the average VIP score is 1, variables whose 
value is greater than one are then considered important.  Alternatively, the absolute value 
of the regression coefficient calculated in the PLS algorithm may be used to rank each 
variable, which describes the relationship between the data loadings and the class label 
in discriminant analysis.  Finally, a method recently proposed by Li and coworkers termed 
CARS was explored as an alternative variable selection protocol.  CARS aims to generate 
calibration models with variable subsets, with predictive power used to determine the 
optimal variable collection34.  A variable subset is selected from the model with the best 
prediction performance.   
Each variable selection protocol was applied to each model generated, and thus 
1000 variable collections were obtained.  All variables selected by CARS were examined 
and the frequency with which a variable was selected was calculated.  In the case of VIP 
and regression coefficient ranked variables, only the top 2% of variables from each model 
were collected (therefore VIP score > 4.26), followed by calculation of the frequency of 
selection (summarized in Table 5.2).  Regardless of the variable selection protocol, 
variables that appeared in at least 50% of the models generated were considered 
important.  This resulted in a collection of 21, 21, and 29 variables for the VIP, regression 
coefficient, and CARS variable selection protocols, respectively.  It was observed that the 
21 variables identified using VIP scores were identical to those selected using regression 
coefficients.  Additionally, 12 variables were found to be common with the CARS variable 
list.  Selecting these variable subsets, logistic regression analysis was performed and 





coefficient and CARS variables, respectively (Figure 5.3).  Additionally, 2CV PLS-DA with 
permutation analysis was performed utilizing the regression coefficient and CARS 
variable subsets, with the results presented in Figure 5.4 and summarized in Table 5.1.  
Clearly, the predictive power of the models was enhanced when selecting variable 
subsets, with particular improvement using the CARS variable subset.  
Table 5.2 The number of variables selected for each data treatment procedure and variable selection 
protocol. 
Values in parentheses are the total number of unique variables identified over the 1000 models generated, 
while the second value indicates the number of variables that appeared in at least 50% of the models 
generated. 




Autoscaled 21 (723) 21 (692) 29 (1891) 
Scaled wrt biopsy-
negative 












Figure 5.3 Logistic regression analysis performed on the auto-scaled NMR data. 
Taking(a) CARS variables and (b) regression coefficient ranked variable subsets identified from 2CV-PLS-
DA analysis.  ROC curves were generated using the first 10, 20, and 29 variables of the CARS subset, and 
the first 5, 10, 15, and 21 variables of the regression coefficient ranked subset.  The corresponding AUC 







Figure 5.4 Distributions of the number of misclassifications, Q2, and AUC after 2CV-PLS-DA 
modeling using variable subsets. 
The NMR data was auto-scaled prior to modeling.  The subsets are the CARS variable subset (a-c), 
regression coefficient ranked subset (d-f), and the VIP ranked subset (g-i).  In all cases, 1000 models were 
generated using the correct class labels (red) and 500 models were generated using permuted class labels 
(blue).  The distributions using the correct class labels were all significantly different in comparison with the 
permuted distributions (p < 0.0001 for each parameter and each subset).  The data is summarized in Table 
5.3, and the number of variables included in each model is given in Table 5.2.   
5.4.2 Variable changes relative to biopsy-negative data 
 The effect of centering and scaling all variable with respect to the mean and 
standard deviation of the normal samples (i.e. biopsy-negative) is a common approach to 
gain insight into variables whose levels are different specifically in comparison with 
normal samples.  Holding all modeling procedures otherwise constant, the resulting 





predictive performance was observed to slightly increase when compared to permutation 
test.  Variable selection resulted in 34, 31, and 9 signals appearing in at least 50% of the 
models, ranked according to VIP scores (resulting in scores > 2.46 collected), regression 
coefficients, and CARS respectively (Table 5.2).  In contrast to the auto-scaled data, all 
VIP ranked variables were unique in comparison with the regression coefficient ranked 
signals, while 5 of the 9 CARS selected variables were also selected utilizing regression 
coefficient ranking.  Interestingly, only modest improvement in modeling parameters was 
observed when selecting variable subsets (Table 5.3).  In particular, CARS failed to 
improve the modeling parameters as observed with the auto-scaled data, perhaps a result 
of the severe reduction in modeled variables.  This is in contrast to the VIP score variable 
subset, where the increase in modeled variables degraded the classification parameters 
in comparison with the auto-scaled data.  Close examination of the correct classification 
rates for each class (biopsy-negative and biopsy-positive) revealed a high rate for the 
biopsy-negative samples, but a poor rate for the biopsy-positive samples, contributing to 
an overall poor classification rate (Table 5.4).  This is particularly true for the VIP variable 







Table 5.3 Summary of model performance parameters for 2CV-PLS-DA modeling based on NMR 
data that was centered and scaled relative to the biopsy-negative samples.    
Using the original labels, 1000 models were generated while 500 models were generated using the 
permuted labels.  All values are reported as mean ± standard deviation.  In the case of permuted data, 
mean parameter values were first calculated over the 20 models per label permutation followed by mean ± 
standard deviation calculation over all 500 permutations.   
 Data set Misclassification Q2 AUC 
Original 
Labels 
Full 32 ± 4 0.01 ± 0.11 0.74 ± 0.05 
CARS 27 ± 4 -0.03 ± 0.13 0.74 ± 0.04 
Reg Coeff 27 ± 4 0.06 ± 0.11 0.80 ± 0.04 
VIP 41 ± 5 -0.4 ± 0.4 0.71 ± 0.04 
Permuted 
Labels 
Full 47 ± 5 -4 ± 6 0.49 ± 0.04 
CARS 48 ± 3 -5 ± 3 0.49 ± 0.03 
Reg Coeff 49 ± 3 -3 ± 1 0.49 ± 0.03 












Table 5.4 Correct classification rates calculated for each model.  After each model was determined, 
it was used to predict the classes of the test data set.   
This was done over the 1000 models generated, and the number of times each sample was part of the test 
set and classified correctly was determined.  Classification rates were then calculated for biopsy-negative 
and biopsy-positive samples as individual groups, and over all samples. 







Full 69 ± 34 63 ± 39 65 ± 37 
CARS 86 ± 27 75 ± 37 79 ± 34 
Reg Coeff 69 ± 36 72 ± 40 71 ± 38 





Full 80 ± 32 59 ± 41 66 ± 39 
CARS 74 ± 41 71 ± 41 72 ± 41 
Reg Coeff 88 ± 28 64 ± 45 72 ± 41 
VIP 87 ± 27 41 ± 43 57 ± 44 
 
5.4.3 Variable subset comparisons – univariate statistics & correlations 
 The variable selection protocols identified signals important in multivariate 2CV-
PLS-DA modeling.  Once these signals are identified, it is interesting to determine their 
univariate capability in distinguishing PCa positive versus negative groups.  Wilcoxon 
rank-sum tests were done for each variable and the appropriate data scaling procedure.  
The number of variables deemed significant (i.e. p < 0.05) for each model are summarized 
in Figure 5.5.  A potential explanation for the poor performance of the VIP selected 
variable subset after z-score calculation relative to normal samples is evident.  Despite 





modeling were found to be significant using univariate statistics.  In contrast, the variable 
subset with the best multivariate modeling parameters (auto-scaled data, CARS variable 
selection) was comprised of signals where greater than 50% were significant using 
univariate statistics.   
 
Figure 5.5 Bar plots representing the number of significant and non-significant variables identified 
in each variable subset using univariate statistics (Wilcoxon rank-sum test). 
(a) NMR data was auto-scaled, (b) NMR data was centered and scaled relative to the biopsy-negative 
samples.  All p-values were corrected for multiple comparisons using the Bonferroni correction.  
Significance was tested at  = 0.05.  The shaded bar indicates the number of significant variables and the 
white bar the number of non-significant variables for each subset.   
 
 With the development of variable subsets containing a relatively large number of 
signals, it is reasonable to question whether each signal is acting independently of the 
others.  For example, since these variables are NMR signals it might be assumed that 
multiple resonances from a single molecule may be contributing to the model.  To address 
this point, the two scaled datasets were subjected to a STOCSY analysis and the 
correlation between each signal within each subset of variables was examined39.  In 





correlations with r > 0.9, above which correlations suggest molecular structure 
connectivity40 (Figure 5.6).  However, the VIP data set subjected to normalization and 
scaling relative to biopsy-negative samples strongly deviates from this trend.  A set of 
strong correlations was observed, with a high percentage possessing r > 0.9.  The 
correlated variables primarily involved signals in the range of 3.2 – 3.9 ppm and most 
likely originate from a sugar molecule (e.g. glucose).  This model contains a large number 
of highly correlated signals which may further explain the poor predictive performance 
since a large amount of redundant information is included.   Interestingly the CARS model 
with auto-scaled data (i.e. the best multivariate model) had the lowest ratio of correlated 
signals to total number of variables modeled.  This is an indication that the CARS method 
selected the greatest number of independent variables and thus had the maximum 






Figure 5.6 Correlations between variables within each subset for each data normalization/scaling 
procedure. 
A Pearson correlation coefficient greater than 0.80 was chosen as a threshold.  In the case of the auto-
scaled data, the number of correlations with r > 0.80 was 2, 6, and 6 for the CARS, regression coefficient 
ranked, and VIP ranked variable subsets, respectively.  In the case of the normalization and scaling relative 
to the biopsy-negative data, the number of correlations with r > 0.80 were 1, 5, and 131 for the CARS, 







5.4.4 An optimal biomarker panel for PCa? 
 In total, six sets of signals were nominated as potential biomarker panels.  From 
these variables subsets, 82 unique variables out of 145 were identified and 18 were 
selected in at least 50% of the six data sets.   Boxplots of a selection of these variables 
are given in Figure 5.7, where biopsy-positive cases are seen to be both decreased and 
increased relative to biopsy-negative.  It should be noted that of the 18 common variables, 
none were found uniquely in the data centered and scaled relative to biopsy-negative 
samples.  This is somewhat unexpected since such data processing would be thought to 
amplify the differences between the negative and positive cases.  This suggests that auto-
scaling may be a sufficient data processing protocol.  Nevertheless, the top 18 variables 
were taken as a final variable subset, a so-called ‘master list’ of potential biomarkers 
(Table 5.5).  The modeling procedure was repeated with this master list and the 
performance characteristics are summarized in Table 5.6.  In the case of the auto-scaled 
data, the results are intermediate of those obtained for the regression coefficient and 
CARS model data sets.  This is not entirely unexpected since a large proportion of the 
‘master’ variables are common to both of these lists.  Also encouraging are the results for 
the biopsy-negative centered and scaled data, which are essentially equivalent to the 
auto-scaled results.  Thus through the analysis of two data processing techniques and 
three variable selection procedures, a final list of potential biomarkers has been identified 






Figure 5.7 Representative signal boxplots of selected variables identified in the ‘master list’. 
The intensity was integrated at the signal indicated for the biopsy-negative (N) and biopsy-positive (P) 
spectra after all NMR data were normalized according the PQN procedure.  The Wilcoxon p-values were p 
< 0.0001, p < 0.0001, p = 0.0002, and p = 0.01 for the signals at 1.162, 3.871, 1.134, and 1.362 ppm, 













Table 5.5 ‘Master list’ of differential variables.   























Table 5.6 Summary of model performance parameters for 2CV-PLS-DA modeling based on the 
‘master list’ variable subset.   
Using the original labels, 1000 models were generated while 500 models were generated using the 
permuted labels.  All values are reported as mean ± standard deviation.  In the case of permuted data, 
mean parameter values were first calculated over the 20 models per label permutation followed by mean ± 
standard deviation calculation over all 500 permutations.   





26 ± 4 0.15 ± 0.11 0.80 ± 0.04 





48 ± 3 -2.8 ± 0.9 0.49 ± 0.04 





NMR detection of metabolite markers of PCa has been primarily performed on 
prostate tissue (e.x. vivo or in vitro), prostatic secretions, or seminal fluid.  From these 
studies (and others), citrate, choline containing compounds, spermine, myo-inositol, 
lactate, alanine, omega-6 fatty acids, creatine and various signal ratios of these 
metabolites have been reported as potential markers of PCa.  Interestingly, while each of 
these metabolites possesses a clearly resolved NMR signal, not a single one was 
nominated in our analysis of urine supernatant.  Urine based mass spectrometry has 
identified several metabolites correlated with PCa, however these studies were performed 
on urine sediment.  The sediment from urine collected post-DRE is expected to contain 
prostate cells which may be the source for these signals.  Thus, urine supernatants 
appear to be exhibiting a different metabolomic profile compared to tissue and urine 
sediment profiles and may be a useful orthogonal route to PCa detection. 
Such a biomarker panel is important in the context of PCa since there remains a 
population of PCa cases that are clinically challenging to diagnose.  In an attempt to 
address this issue, it is worth re-emphasizing that ‘normal cases’ in this study referred to 
patients experiencing non-cancerous prostate disorders.  It is common for patients 
possessing such disorders to display elevated levels of PSA, the current clinical standard 
for PCa diagnosis.  This therefore complicates the diagnosis of PCa, and further invasive 
procedures are required.  This study demonstrated the capability of NMR data to 
distinguish PCa patients from the biopsy-negative population.  This suggests that a 
metabolomic analysis of urine (supernatant and sediment separately), a non-invasive 
biospecimen, may be further explored for PCa diagnostic potential.   In combination with 





completely non-invasive clinical test may be on the horizon capable of outperforming PSA 
levels for PCa identification.      
5.5 Conclusion  
It is encouraging that taken what as potential biomarker panels the variable 
subsets perform exceptionally well in differentiating biopsy-negative versus biopsy-
positive profiles.  While it is certainly the case that the variable selection protocols utilized 
here are not completely independent (particularly VIP and regression coefficient ranking), 
a certain level of confidence is gained by more than one method selecting common 
variables.  It is envisioned that a single variable selection protocol will not dominate, and 
instead a combination of techniques will generate the most reliable variable nominations.  
The next challenge becomes signal identification so that the biological significance of 
these variables may be investigated.  Currently, the signal assignments remain unknown, 
pointing to a primary challenge in NMR based urinary metabolomics.  Due to the 
complexity of the samples, assignment is a significant challenge which is slightly 
alleviated by utilizing high magnetic field strengths (900 MHz in this case).  Unfortunately, 
the signals identified appear at low concentration resulting in increased difficulty in 
obtaining suitable multi-dimensional NMR data, which is essential for confident 
assignment of the otherwise unknown resonances.  Speculation of the most likely 
chemical functionality is possible.  For example, the signal centered at 1.164 ppm most 
likely arises from small organic acid molecules containing CH2 moieties.  Nevertheless, 
this study demonstrates the utility of NMR-based metabolomics of urine for the 
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CHAPTER 6  
NMR Spectroscopy Based Metabolic Profiling of Urine for the Non-
invasive Detection of Human Bladder Cancer 
6.1 Abstract 
Diagnosis and surveillance of bladder cancer (BCa) with the combination of 
cystoscopy and urine cytology, currently the gold standard, suffers from poor sensitivity, 
particularly for low-grade tumors leading to invasive follow-up procedures. To explore 
alternate approaches for non-invasive detection of BCa, we performed 1H NMR-based 
global metabolic profiling of urine specimens collected from BCa (n=50) and healthy 
controls (n=35), and identified more than thirty-two differentially expressed metabolites. 
Unbiased, principal component analysis performed on NMR dataset (creatinine-
normalized) showed no clear segregation between control and BCa group. Univariate 
statistical analysis was performed on binned NMR dataset to investigate significantly 
altered 1H chemical shift regions (P < 0.05). Receiver operating characteristic curve was 
generated on these significant chemical regions and only regions with area under the 
curve (AUC) > 0.6 were chosen for inclusion in a panel of metabolic biomarkers. In total 
seven metabolites, 1,2 propanediol (P <0.0001), trimethylamine N-oxide (P <0.007), 
taurine (P <0.01), p-cresol sulfate (P <0.0001), phenylacetylglutamine (P <0.001) and 3-
aminobutyric acid (P <0.006) were significantly elevated, whereas 2-furoylglycine (P 





elevated metabolites showed AUC values ranging from 0.67 to 0.81. Majority of these 
altered metabolites were gut microbial co-metabolites suggesting intimate association of 
gut microbiome dynamics with bladder cancer progression. In summary, our results 
suggest that NMR-based metabolic profiling of bladder cancer urine can be a quick, cost 
effective and promising tool for non-invasive detection of BCa.  
 
6.2 Introduction 
Bladder Cancer (BCa) is the ninth most frequent genito-urinary malignancy 
diagnosed worldwide and fifth leading new cancer diagnosed in the United States1. Of 
newly diagnosed BCa patients having non-muscle invasive papillary disease (i. e. 
restricted to urothelium or lamina propia), a subgroup of high-risk patients will progress 
to lethal, metastatic disease resulting in significant morbidity. Current clinical diagnosis 
and surveillance of BCa rely on urine cytology and cystoscopy followed by histopathology 
of tissue specimens obtained from tumor biopsies, the current gold standard. Cystoscopy 
has only modest sensitivity particularly for low-grade (Ta-T1 stage) tumors2 but adds 
significantly to patients’ discomfort, as well as economic burden. To overcome these 
challenges, alternative strategies are warranted specifically non-invasive diagnostic 
biomarkers that could replace cystoscopy, especially for low-risk patients that can 
accurately predict disease aggressiveness, recurrence and progression. Due to the 
functional, biologically significant relationship between bladder and urine, urine samples 
are ideal and relevant medium for identifying urinary biomarkers for the non-invasive 





Recently transcriptomic and proteomic approaches identified multiple potential 
urinary biomarkers for non-invasive detection of BCa3, 4, 5. While genomic and 
transcriptomic approaches discover aberrations at the DNA, RNA and protein levels, 
metabolomic approaches uncover global changes in low molecular weight metabolites in 
biological samples that occur in response to various environmental and cellular signals. 
Metabolomics studies produce plethora of information that are complementary to those 
obtained from genomics and proteomics and collective information has been used for the 
global assessment of metabolic network within a living system6. Similar to genomics and 
transcriptomics, metabolomics approach has also been used for developing 
diagnostic/prognostic biomarkers for specific diseases7. Generally metabolomic profiling 
has been performed using analytical platforms such as Nuclear Magnetic Resonance 
(NMR) and Mass spectrometry (MS) techniques8 individually or in combination. Both 
these techniques have inherent advantages and disadvantages but can provide 
complementary and supplementary metabolic data that can be used to construct a panel 
of disease-specific biomarkers. Metabolic signatures have been identified in many cancer 
types such as prostate7, esophageal9, pancreatic ductal10, 11, colon12 among others.  
Recently we performed metabolic profiling of bladder tissues using high-resolution 
magic angle spinning (HR-MAS) NMR to distinguish BCa tissue metabolome from that of 
benign tissues8. Only a limited number of metabolomics studies exploring urinary 
metabolic signatures for human bladder cancer have been performed till date using 
GC/TOFMS (gas chromatography/time-of-flight MS) and LC-MS (liquid chromatography-
MS) 13, 14, 15. One NMR study reportedly identified elevated taurine levels in BCa urine 





for noninvasive detection of BCa, we performed NMR-based global metabolic profiling of 
urine samples collected from patients and healthy volunteers. We identified dysregulation 
in several metabolites in BCa urine samples that can potentially be developed into a 






6.3 Materials and Methods 
6.3.1 Urine samples collection 
Urine samples were collected in sterile containers either during a clinic visit or prior 
to transurethral resection of bladder tumor (TURBT) or cystectomy from BCa patients 
enrolled in the bladder cancer program in the Department of Urology at the University of 
Michigan. All urine samples were collected with prior approval from Institutional Review 
Board and informed consent from patients. The tumor stage and grade were confirmed 
by histopathological evaluation of tumor biopsies obtained through cystoscopy, which was 
established according to World Health Organization and International Society of Urologic 
Pathology Standards17. Normal urine samples were collected from healthy volunteers 
who do not have symptoms of bladder cancer or other urological disorders. Immediately 
after urine collection, the samples were stored at -80C until sample preparation for 
metabolomic analysis. Detailed information of the patients’ clinico-pathologic parameters 
is included in Table 6.1. 
Table 6.1 Clinical Characteristics of the BCa Patients. 
Characteristics BCa patients Normal 
No. of Patients 50 35 
Gender (Male/Female) 44/6 25/10 
Age (Mean ± SD) 68.1 ± 10.8 years 55.2 ± 17.6 years 
Pathological stage/grade   
Tis 10  
Ta – Low grade/High grade 5/15  
T1 10  







K2HPO4, KH2PO4, 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP), 
Deuterium oxide (D2O), 3-aminoisobutyric acid, creatinine, Dimethylformamide and N-
methyl-N-(tert-butylmethylsilyltrifluoroacetamide) (MtBSTFA) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).    
6.3.3 Sample preparation for NMR Spectroscopy 
Urine samples stored at -80C were obtained and allowed to thaw at room 
temperature. 600 µL of each sample was centrifuged (10,000 rpm, 10 min at 4C) and 
450 µL of clear supernatant liquid was transferred into a 5 mm NMR tube (Wilmad, NJ, 
USA). 50 µL D2O containing a mixture of 1 M phosphate buffer (pH 7.2) and 100 µg TSP 
was thoroughly mixed with 450 µL urine in NMR tube and analyzed by NMR. 
6.3.4 NMR Spectroscopy 
All the NMR experiments were carried out on a Bruker Avance 900 MHz NMR 
spectrometer (Bruker BioSpin, Karlsruhe, Germany) equipped with a 5 mm HCN TCI 
cryo-probe at 298 K temperature and NMR spectra were processed using Bruker 
TOPSPIN 2.1 software. One-dimensional (1D) 1H spectra were acquired using a one-
pulse experiment with water presaturation during relaxation delay. Typical parameters 
used were: pulse length- 45; spectral width- 14492.75 Hz (16.1091 ppm); data points- 
32078; relaxation delay- 2s; number of transients- 256. The resultant free induction 
decays were zero filled with 32,768 points and multiplied by an exponential window 
function with a line broadening factor of 0.3 Hz prior to Fourier transformation, and the 





For chemical assignment of urine metabolites, two-dimensional (2D) experiments 
such as 1H-1H total correlation spectroscopy (TOCSY) and 1H-13C heteronuclear single 
quantum coherence spectroscopy (HSQC) were performed on urine samples. 2D TOCSY 
spectra were acquired in the phase-sensitive time proportional phase incrementation 
(TPPI) mode with MLEV17 spin lock mixing time of 70 ms. Parameters used for 1H-1H 
TOCSY: spectral width in both dimension- 14492.75 Hz; relaxation delay- 1.5s; data 
points- 2048; number of transients- 64; number of t1 increments- 256. 1H-13C HSQC 
spectra were acquired using phase-sensitive echo-antiecho mode: spectral width in 1H 
and 13C dimension- 14492.75 Hz and 40722.58 Hz, respectively; data points- 2048; 
number of transients- 128; number of t1 increments- 256; relaxation delay- 1.5 s. Both 
TOCSY and HSQC data were zero filled to 2048 × 1024 matrix and Fourier transformed 
along both dimensions after multiplying the data by a squared sine-bell window function 
shifted by /2. 
6.3.5 Statistical analysis 
Before performing any statistical analyses, the chemical shift regions of 0.5 – 10.0 
ppm of all the 1H NMR spectra of urine samples were converted to ASCII-files and the 
spectral regions of residual water and urea (4.5 – 6.0 ppm) were excluded in further 
analyses. All the 1H spectra were normalized to creatinine signal at 3.05 ppm and were 
aligned using variable reference-interval correlated shifting (Vr-icoShift)18. Principal 
component analysis (PCA) was performed with mean-centered data pretreatment and the 
results were depicted as scores and loadings plot (The Unscrambler V10.1, CAMO, Oslo, 
Norway). For univariate statistical analysis (SPSS v 21, SPSS Inc., Chicago, IL, USA), 





variable was compared between normal and BCa samples using Mann-Whitney U test 
and P < 0.05 was considered statistically significant. Further statistically significant 
chemical shift variables were selected and the corresponding intensities of metabolites 
were calculated separately for normal and BCa urine samples and subjected to receiver 
operating characteristic (ROC) curve analysis. The metabolites with AUC > 0.60 were 
considered differentially altered metabolite. 
6.3.6 Z-scores 
To visualize overall changes in the urinary metabolic pattern, z-scores were 
calculated using creatinine-normalized binned NMR data. The mean and standard 
deviation of the normal samples were calculated for each binned chemical shift variable. 
Further, each normal and BCa sample was centered by the normal mean and scaled by 
the normal standard deviation.    
6.3.7 GC-MS Targeted Analysis 
Urine samples were homogenized in methanol after spiking labeled internal 
standards (d3-aminoisobutyric acid and d1 creatinine) and placed on a shaker overnight 
at 4oC. The extraction was carried out using 1:1 molar ratio of water/chloroform at room 
temperature. The aqueous methanolic layer was collected and dried completely under 
nitrogen. The dried methanolic amino acid residue was azeotroped twice by adding 100 
L dimethylformamide (DMF), vortexing, and then drying in a speed vac for 30 minutes. 
100 L of DMF and N-methyl-N-(tert-butylmethylsilyltrifluoroacetamide (MtBSTFA) + 1% 
t-butyl-dimethylchlorosilane was added to the dried sample, capped and incubated at 
60C for 1 hr and then resuspended in ethyl acetate before injection into a GC-MS. 





creatinine. The amount of metabolite in the sample was calculated by measuring the peak 
area of the native metabolite normalized to the area of the peak for the isotope-labeled 
internal standard. Creatinine was used to normalize 3-aminoisobutyric acid levels. 
6.4 Results 
6.4.1 Clinical characteristics of BCa patients and urine samples 
BCa patient urine samples were procured from the Bladder Cancer Program at 
Department of urology, University of Michigan. Fifty BCa patients at various stages of 
BCa were included in the study: ten patients with non-invasive flat carcinoma (Tis), twenty 
patients with non-invasive papillary carcinoma (Ta) with five low- and fifteen high grade, 
ten were staged at T1 and ten at T2. For comparison, urine samples were collected from 
thirty-five healthy volunteers who had no symptoms of urological disease. Detailed clinical 
parameters of patients are shown in Table 6.1. 
6.4.2 1H NMR profiling of BCa and normal urine samples 
1H NMR spectra were obtained for fifty BCa and thirty-five normal urine samples. 
The overall workflow of 1H NMR metabolic profiling of urine samples is shown in Figure 
6.1. The chemical shift assignment of various metabolites was carried out using a 
combination of 2D 1H-1H TOCSY and 1H-13C HSQC, Human Metabolome Database 
(HMDB)19, Biological Magnetic Resonance Data Bank (BMRB)20, MetaboID21 and 
literature chemical shift database22, 23. Figure 6.2 depicts a representative 1H NMR 
spectra (normalized to creatinine) of two each from normal (in black) and BCa patients 
(in red) with chemical assignment of various metabolites. A wide range of metabolites 





nicotinamide metabolites, ketone bodies, short-chain fatty acids, metabolites related to 
osmoregulation, gut microbial metabolites and several other endogenous metabolites. 
 
Figure 6.1 Flow chart showing an overview of metabolomics workflow in NMR-based metabolic 







Figure 6.2 Representative 900 MHz 1H NMR spectra of urine samples from healthy controls (bottom 
two in black) and bladder cancer (top two in red) with chemical shift assignment of various 
metabolites. 
The spectral regions of residual water and urea (4.6 – 6.5 ppm) were not shown and all the spectra were 
normalized to 1H peak of creatinine at 3.05 ppm. Chemical shift assignments were: 1) Leucine, 2) 1,2 
propanediol, 3) Threonine, 4) 3-aminoisobutyric acid, 5) Lactate, 6) 2-hydroxyvalerate, 7) Alanine, 8) 
Phenylacetylglutamine, 9) Acetoacetate, 10) Pyruvate, 11) Oxaloacetate, 12) p-Cresol sulfate, 13) Citrate, 
14) Dimethylamine, 15) Dimethylglycine, 16) Trimethylamine, 17) Creatinine, 18) Malonate, 19) 
Trimethylamine N-oxide, 20) Scyllo-Inositol, 21) Taurine, 22) Glycine, 23) Guanidoacetate, 24) Trigonelline, 
25) 2-furoylglycine, 26) 3-methylhistidine, 27) 1-methylhistidine, 28) Hippurate, 29) Hypoxanthine, 30) 
Formate, 31) N-methylnicotinamide, 32) Betaine. 
 
 
6.4.3 Statistical Analysis of urine 1H NMR data 
In order to visualize the differential metabolic profiles of normal and BCa group, 
unsupervised PCA was performed on the creatinine-normalized NMR data; however, 
PCA score plot did not show clear segregation between normal and BCa samples. We 
then performed univariate statistical analysis on NMR dataset to identify differentially 
expressed metabolites in BCa samples relative to control samples. After removing 





0.004 ppm bins resulting in 1932 variables. Each of these variables was compared 
between normal and BCa groups using U test and only statistically significant variables 
(P < 0.05) were selected for ROC curve analysis. Further, the variables having area under 
the curve (AUC) > 0.6 were selected for inclusion in a multiplex panel of markers for BCa. 
6.4.4 Urinary Metabolic Signatures of Bladder Cancer 
Z-score plots of 1932 bins of normal (blue) and BCa groups (red) normalized to 
the normal mean and scaled to normal standard deviation are shown in Figure 6.3 where 
overall changes in the 1H signal intensities between the two groups can be visualized. 
Furthermore, variables having AUC > 0.6 were used to identify the metabolites from these 
chemical shift values. These chemical shift values corresponded to seven metabolites: 
1,2 propanediol, trimethylamine N-oxide (TMAO), taurine, 2-furoylglycine, p-cresol sulfate, 
phenylacetylglutamine (PAGN) and 3-aminoisobutyric acid (ABA). Relative intensities of 
these significantly elevated metabolites (with respect to creatinine levels) were calculated 
separately for normal and BCa groups using full resolution creatinine-normalized NMR 
data set. A selective non-overlapping 1H signal from each metabolite was used to 
calculate the ratio of metabolite to creatinine. 1H signal used for quantification were: 1,2 
propanediol (1.158 ppm), taurine (3.44 ppm), furoylglycine (6.656 ppm), p-cresol sulfate 
(7.295 ppm) and phenylacetylglutamine (7.438 ppm). Since the singlet 1H signal of TMAO 
(3.28 ppm) was overlapping with that of S-CH2 triplet signal of taurine, the intensity of N-
CH2 triplet of taurine (3.44 ppm) was subtracted from the total intensity of TMAO (N-(CH3) 
+ taurine (S-CH2) to obtain the correct intensity of TMAO. Similarly, 1H signals of 3-
aminoisobutyric acid also overlapped with other 1H signals of many other metabolites, 





used targeted GC-MS analysis to measure the levels of 3-aminoisobutyric acid with 
respect to creatinine. 
 
Figure 6.3 z-score plots of 1H NMR data (1932 bins) of normal and bladder cancer urine samples. 
Both sample groups were normalized to the mean and scaled to standard deviation of normal samples. 
Significant variation in the z-scores of bladder cancer urine can be observed and altered 1H signal intensities 
are highlighted with corresponding metabolites.        
  
Figure 6.4 shows bar plots ratio of seven differentially expressed metabolites with 
respect to creatinine levels. Six metabolites, 1,2 propanediol (P < 0.0001), TMAO (P < 
0.007), taurine (P < 0.01), p-cresol sulfate (P < 0.0001), phenylacetylglutamine (P < 0.001) 
and 3-aminoisobutyric acid (P < 0.006) were significantly elevated and furoylglycine (P < 





curves of these differential metabolites are shown in Figure 6.5 and corresponding AUC 
values varied from 0.67 to 0.81. 
 
Figure 6.4 Box plot showing the levels of seven urine metabolites (normalized to creatinine) that were 
measured in healthy and bladder cancer urine. 
The level of 3-aminoisobutyric acid was measured using GC-MS and rest of the six metabolites was 
measured by NMR. In each case, the ratio of metabolite/creatinine was compared between normal and 
bladder cancer group using Mann-Whitney U test and six metabolites were significantly elevated and 2-







Figure 6.5 ROC curves generated from metabolite/creatinine ratio of six metabolites measured by NMR (A) and 
(B) 3-aminoisobutyric acid measured from GC-MS. 
AUC values for 1,2 propanediol, TMAO, taurine, 2-furoylglycine, p-cresol sulfate, phenylacetylglutamine 
and 3-aminoisobutyric acid are 0.80, 0.69, 0.67, 0.72, 0.81, 0.73 and 0.74, respectively.   
 
6.5 Discussion 
Current diagnosis of bladder cancer based on cystoscopy and urine cytology suffer 
from low sensitivity especially towards low-grade tumors; moreover, cystoscopy is one of 
the most expensive procedures3. Therefore the discovery of non-invasive biomarkers that 
are efficient and cost-effective would be of significant value. Utilize metabolomics 
approach, we recently performed HR-MAS NMR metabolic profiling of BCa and benign 
tissues, and identified several dysregulated metabolites specifically in BCa that could 
potentially be employed to distinguish tumor from benign tissues8. Extending upon those 
studies here, we conducted a NMR-based metabolomics study focused on unbiased 
metabolic profiling of BCa and normal urine in an effort to develop a non-invasive 
diagnostic tool. Due to the functional significance of bladder, urine is an ideally suited 
specimen for exploring urinary biomarkers for the non-invasive detection of BCa. We 





range of metabolites were identified. In the present study we adopted creatinine 
normalization based on the fact that creatinine clearance in bladder cancer urine is 
constant and comparable to normal urine24. Unsupervised PCA performed on creatinine-
normalized NMR dataset did not segregate normal and BCa urine samples. If PCA fails 
to segregate different classes, generally supervised statistical analysis such as partial 
least square discriminant analysis (PLS-DA) and OPLS-DA are performed. However we 
did not pursue any of these supervised analyses to avoid potential over-fitting in 
segregating normal and BCa groups.  Instead we performed U test (P < 0.05) followed by 
ROC analysis (AUC > 0.6) which revealed differential expression of seven metabolites, 
1,2 propanediol, TMAO, taurine, p-cresol sulfate, phenylacetylglutamine, 3-
aminoisobutyric acid and 2-furoylglycine. 
Elevated taurine in BCa urine observed in the present study is consistent with 
recent NMR report on bladder cancer16. Notably, taurine is the only common metabolite 
elevated in both BCa urine and tissues8. Taurine is associated with multiple biological 
processes such as osmoprotection, volume-activated organic flux pathways25, 
antineoplastic and antioxidant properties26, and gut microbial metabolism27. Although it is 
not certain how taurine is involved in BCa development or progression, bladder cancer 
tissues experience oxidative stress8, 28 and elevated taurine may be associated with 
antioxidant pathway. Increased excretion of TMAO in BCa urine may be correlated with 
osmotic stress mechanism in bladder cancer where TMAO acts as an omsoprotectant. 
The metabolite 2-furoylglycine, a conjugation product of glycine and 2-furoic acid was not 
detected in any BCa samples but detected only in normal urine samples. Elevated 





chocolates and heated fruit juice29 but its correlation with bladder cancer remains 
unknown. Similarly the specific mechanism associated with increased excretion of 1,2 
propanediol in bladder cancer urine is also unclear. 
The gut microbial co-metabolites such as phenylacetylglutamine, p-cresol sulfate 
and 3-aminoisobutyric acid were significantly elevated in BCa urine. The correlation of 
these metabolites with human gut microbiome were described27 wherein 
phenylacetylglutamine and 4-cresol sulfate are linked with Subdoligranulum variable BI-
114 and Bifidobacterium pseudocatenulatum, and 3-aminoisobutyric acid is linked with 
three gut microbes, Bacteroidetes thetaiotaomicron, Bacteroidetes uniformis and 
Ruminococcus bromii. Dysregulation of human microbiota has been reported in various 
diseases and associated with drug metabolism30. The association of gut microbes with 
colon31 and liver cancer32 has also been reported. Our present study clearly indicates a 
correlation between gut microbial metabolites and bladder cancer and warrants further 
investigation. Many of the significantly altered metabolites observed in our NMR study 
have not been previously reported in mass spectrometry-based metabolomics studies of 
bladder cancer13, 14, 15. 
In the present study, we explored the possibility of NMR-based metabolomics 
approach for the non-invasive detection of bladder cancer in urine samples. Due to limited 
sample size we did not analyze metabolite levels across various stages and grades of 
bladder cancer. Ideally a large sample cohort involving multi-institutions would be 
required for a validation study. We are acquiring additional urine samples from bladder 
cancer patients and healthy volunteers to conduct a validation study of seven metabolites 





significantly altered metabolites, it will be a straightforward for other research groups to 
validate these metabolites in urine samples of bladder cancer patients.  The panel of 
seven urinary metabolite biomarkers reported here from NMR study complements the 
study by Putluri et al15 and Pasikanti et al13, 14. 
We believe that NMR-based metabolic profiling of bladder cancer urine is a 
promising approach that warrants further independent validation and eventual 
development as an efficient and cost effective diagnostic tool. Importantly, our results 
uncovered the association of gut microbiome with bladder cancer progression.  
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